Disorders of pituitary gland, other and/or unspecified

E4_PITUDISNAS

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E23.6, E23.7 Hospital discharge: ICD-9 — 253[8-9] Hospital discharge: ICD-8 — 2539 Hospital discharge: excluded ICD-8 — 25390 Cause of death: ICD-10 — E23.6, E23.7 Cause of death: ICD-9 — 253[8-9] Cause of death: ICD-8 — 2539 Cause of death: excluded ICD-8 — 25390 2 out of 7 registries used, show all original rules.	221
4. Check minimum number of events None	221
5. Include endpoints None	221
6. Filter based on genotype QC (FinnGen only)	214

Control definitions (FinnGen only)

Control exclude: E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2

NAME	E4_PITUDISNAS
CONTROL_EXCLUDE	E4_ENDOGLAND
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E23[6-7]
HD_ICD_9	253[8-9]
HD_ICD_8	2539
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL	25390
COD_MAINONLY
COD_ICD_10	E23[6-7]
COD_ICD_9	253[8-9]
COD_ICD_8	2539
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL	25390
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Disorders of pituitary gland, other and/or unspecified based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	1524	908	598
Only index persons	1235	751	484
Unadjusted period prevalence (%)
Whole population	0.02	0.03	0.02
Only index persons	0.02	0.03	0.02
Median age at first event (years)
Whole population	43.56	42.80	44.54
Only index persons	39.94	38.95	41.48

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	214	132	82
Unadjusted period prevalence (%)	0.04	0.05	0.04
Median age at first event (years)	43.19	40.98	46.75

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
221: Matched controls
2210

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

H02AB09

ATC

hydrocortisone; systemic

106.0

154.0

E23.6

ICD-10 Finland

Other disorders of pituitary gland

+∞

124.0

107

101

Kela drug reimbursment

Anterior pituitary hypofunction

+∞

63.7

AA4CG

NOMESCO Finland

Extensive MRI examination of sella turcica with high intensity magnet

+∞

61.4

E23.00

ICD-10 Finland

Panhypopituitarism

+∞

57.9

D35.2

ICD-10 Finland

Benign neoplasm: Pituitary gland

363.7

57.1

E23.7

ICD-10 Finland

Disorder of pituitary gland, unspecified

+∞

55.6

H03AA01

ATC

levothyroxine sodium; systemic

6.5

43.2

116

322

AAE10

NOMESCO Finland

Transsphenoidal total or partial excision of intracranial lesion

192.9

32.7

G03BA03

ATC

testosterone; systemic, rectal, sublingual, transdermal

10.7

32.2

102

Kela drug reimbursment

Diabetes insipidus

+∞

31.0

25399

ICD-8 Finland

Diseases of pituitary gland, Other and unspecified

+∞

27.7

25398

ICD-8 Finland

Diseases of pituitary gland, Alii definiti

+∞

26.6

D44.3

ICD-10 Finland

Neoplasm of uncertain or unknown behaviour: Pituitary gland

+∞

25.5

E22.1

ICD-10 Finland

Hyperprolactinaemia

+∞

22.3

E23.2

ICD-10 Finland

Diabetes insipidus

+∞

21.2

H01BA02

ATC

desmopressin; nasal, systemic, sublingual

21.0

21.1

AA4BG

NOMESCO Finland

MRI examination of sella turcica with high intensity magnet

218.8

19.9

E23.09

ICD-10 Finland

Pituitary insufficiency NOS

+∞

18.0

N04BC06

ATC

cabergoline; oral

103.5

17.9

H01AC01

ATC

somatropin; parenteral

+∞

16.9

301

Kela drug reimbursment

Growth hormone

+∞

13.7

Z03.80

ICD-10 Finland

Observation for other suspected diseases and conditions

12.1

13.4

G02CB01

ATC

bromocriptine; systemic

18.2

13.3

E23.05

ICD-10 Finland

Lack of TSH

+∞

12.6

E34.9

ICD-10 Finland

Endocrine disorder, unspecified

+∞

12.6

XCK00

NOMESCO Finland

Perimetry

4.8

12.1

E23.03

ICD-10 Finland

Lack of ACTH

+∞

11.6

ZXC86

NOMESCO Finland

Use of endoscopic device

63.1

10.7

AA1CG

NOMESCO Finland

Extensive MRI examination of brain with high intensity magnet

3.6

10.3

116

E23

ICD-10 Finland

Hypofunction and other disorders of pituitary gland

+∞

9.4

E23.08

ICD-10 Finland

Hypopituitarism

+∞

9.4

2538X

ICD-9 Finland

Disorders of the pituitary gland and its hypothalamic control, Other disorders of the pituitary and other syndromes of diencephalohypophyseal origin[MORBUS HYPOPHYSEOS SEU HYPOTHALAMI ALIA]

+∞

9.4

E23.01

ICD-10 Finland

Isolated deficiency of growth hormone

+∞

9.4

E23.0

ICD-10 Finland

Hypopituitarism

+∞

8.4

AA4DG

NOMESCO Finland

Very extensive MRI examination of sella turcica with high intensity magnet

+∞

8.4

AA4CM

NOMESCO Finland

Extensive MRI examination of sella turcica with 3 Tesla magnet

+∞

8.4

25320

ICD-8 Finland

Diseases of pituitary gland, Chromophobe adenoma, pituitary

+∞

8.4

E23.06

ICD-10 Finland

Empty sella

+∞

8.4

2532A

ICD-9 Finland

Disorders of the pituitary gland and its hypothalamic control, Panhypopituitarism[PANHYPOPITUITARISMUS]

+∞

8.4

121

Kela drug reimbursment

Severe hypofunction of sexual glands

10.0

7.9

E87.1

ICD-10 Finland

Hypo-osmolality and hyponatraemia

4.5

7.6

E23.04

ICD-10 Finland

Hypogonadotropic hypogonadism

26.0

7.6

104

Kela drug reimbursment

Thyroid insufficiency

3.6

7.5

G02CB03

ATC

cabergoline; oral

82.8

7.5

22620

ICD-8 Finland

Benign neoplasm of endocrine glands, Pituitary gland and craniopharyngeal duct (pouch)

+∞

7.3

D35.31

ICD-10 Finland

Cyst in Rathke's pocket

+∞

7.3

2539X

ICD-9 Finland

Disorders of the pituitary gland and its hypothalamic control, Unspecified

+∞

7.3

N91.1

ICD-10 Finland

Secondary amenorrhoea

23.3

6.7

D35.30

ICD-10 Finland

Craniopharyngoma

+∞

6.3

E22.0

ICD-10 Finland

Acromegaly and pituitary gigantism

+∞

6.3

GD1AA

NOMESCO Finland

Thorax X-ray examination

2.0

6.2

113

754

UJD10

NOMESCO Finland

Esophagoscopy, gastroscopy and duodenoscopy

2.1

6.0

426

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Endocrinology
46 [38004485]

2.3e+00

3.0e+00

2.4e+00

1.0e+50

3.7e+00

3.9e+00

3.2e+00

cases:17.34%

controls:2.16%

cases:23.12%

controls:1.52%

cases:6.36%

controls:0.58%

cases:40.46%

controls:0.00%

cases:12.14%

controls:0.35%

cases:46.47%

controls:1.78%

cases:45.45%

controls:3.42%

143

1675

133

1686

162

1702

103

1712

152

1706

1655

1470

hydrocortisone; oral, parenteral
H02AB09 [21602737]

2.5e+00

3.7e+00

—

4.7e+00

3.3e+00

cases:15.03%

controls:1.40%

cases:17.34%

controls:0.53%

—

cases:27.65%

controls:0.36%

cases:31.17%

controls:1.64%

147

1688

143

1703

—

123

1679

106

1497

Neurology
13 [38004458]

1.0e+00

2.2e+00

2.6e+00

1.0e+50

3.4e+00

2.0e+00

1.4e+00

cases:16.76%

controls:6.89%

cases:21.39%

controls:2.98%

cases:5.20%

controls:0.41%

cases:8.67%

controls:0.00%

cases:8.09%

controls:0.29%

cases:15.88%

controls:2.61%

cases:20.78%

controls:5.85%

118

144

1594

136

1661

164

1705

158

1712

159

1707

143

1641

122

1433

Outpatient Visit
OP [9202]

4.8e-01

1.2e+00

7.8e-01

5.7e+00

1.5e+00

1.3e+00

1.2e+00

cases:68.21%

controls:57.13%

cases:67.63%

controls:37.68%

cases:17.34%

controls:8.76%

cases:58.38%

controls:0.47%

cases:28.90%

controls:8.18%

cases:70.59%

controls:39.29%

cases:85.71%

controls:65.11%

118

978

734

117

645

1067

150

143

1562

101

1704

140

123

1572

120

662

1023

132

991

531

levothyroxine sodium; oral, parenteral
H03AA01 [21602754]

1.5e+00

1.7e+00

1.4e+00

—

2.2e+00

2.3e+00

2.4e+00

cases:21.39%

controls:5.90%

cases:25.43%

controls:5.96%

cases:7.51%

controls:1.99%

—

cases:13.87%

controls:1.75%

cases:38.82%

controls:6.11%

cases:46.75%

controls:7.29%

101

136

1611

102

129

1610

160

1678

—

149

1682

103

104

1582

111

1411

Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]

2.4e+00

—

1.0e+50

4.3e+00

3.3e+00

cases:7.51%

controls:0.76%

—

cases:9.25%

controls:0.00%

cases:21.18%

controls:0.36%

cases:21.43%

controls:0.99%

160

1699

—

157

1712

134

1679

121

1507

Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]

2.9e-01

1.2e+00

2.9e+00

—

2.7e+00

1.6e+00

9.1e-01

cases:16.76%

controls:13.14%

cases:19.65%

controls:6.72%

cases:10.98%

controls:0.70%

—

cases:9.83%

controls:0.70%

cases:25.88%

controls:6.59%

cases:34.42%

controls:17.41%

225

144

1487

115

139

1597

154

1700

—

156

1700

111

126

1574

265

101

1257

Neurosurgery
14 [38004459]

1.5e+00

2.6e+00

—

1.0e+50

—

3.1e+00

2.1e+00

cases:6.94%

controls:1.58%

cases:8.09%

controls:0.64%

—

cases:2.89%

controls:0.00%

—

cases:13.53%

controls:0.71%

cases:13.64%

controls:1.91%

161

1685

159

1701

—

168

1712

—

147

1673

133

1493

testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]

2.5e+00

—

3.4e+00

cases:7.51%

controls:0.64%

—

cases:12.35%

controls:0.47%

cases:14.94%

controls:0.59%

160

1701

—

149

1677

131

1513

Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]

2.1e+00

2.7e+00

—

2.5e+00

1.9e+00

cases:4.62%

controls:0.58%

cases:4.05%

controls:0.29%

—

cases:3.53%

controls:0.30%

cases:7.14%

controls:1.12%

165

1702

166

1707

—

164

1680

143

1505

Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]

1.6e+00

2.7e+00

—

3.4e+00

2.3e+00

cases:4.05%

controls:0.82%

cases:5.78%

controls:0.41%

—

cases:10.00%

controls:0.36%

cases:11.04%

controls:1.25%

166

1698

163

1705

—

153

1679

137

1503

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

5.0e-01

1.1e+00

2.2e+00

—

2.5e+00

1.4e+00

1.1e+00

cases:9.83%

controls:6.19%

cases:8.67%

controls:3.10%

cases:4.62%

controls:0.53%

—

cases:4.62%

controls:0.41%

cases:11.76%

controls:3.09%

cases:20.78%

controls:7.82%

106

156

1606

158

1659

165

1703

—

165

1705

150

1633

119

122

1403

Internal Medicine
11 [38004456]

1.0e+00

1.4e+00

1.3e+00

—

2.4e+00

1.9e+00

1.3e+00

cases:36.99%

controls:17.23%

cases:23.70%

controls:6.83%

cases:5.20%

controls:1.46%

—

cases:11.56%

controls:1.17%

cases:31.18%

controls:6.65%

cases:42.21%

controls:16.16%

295

109

1417

117

132

1595

164

1687

—

153

1692

112

117

1573

246

1276

prednisolone
A07EA01 [21600653]

1.2e+00

—

2.3e+00

1.5e+00

1.1e+00

cases:22.54%

controls:7.83%

cases:9.25%

controls:2.98%

—

cases:6.36%

controls:0.64%

cases:11.18%

controls:2.79%

cases:18.83%

controls:7.42%

134

1578

157

1661

—

162

1701

151

1638

113

125

1409

prednisolone; oral, parenteral
H02AB06 [21602734]

1.2e+00

—

2.3e+00

1.5e+00

1.0e+00

cases:22.54%

controls:7.83%

cases:9.25%

controls:2.98%

—

cases:6.36%

controls:0.64%

cases:11.18%

controls:2.79%

cases:18.18%

controls:7.36%

134

1578

157

1661

—

162

1701

151

1638

112

126

1410

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

1.5e-01

9.7e-01

1.7e+00

—

3.2e+00

9.9e-01

5.7e-01

cases:12.72%

controls:11.10%

cases:13.29%

controls:5.49%

cases:5.78%

controls:1.11%

—

cases:8.09%

controls:0.35%

cases:14.71%

controls:5.99%

cases:22.73%

controls:14.26%

190

151

1522

150

1618

163

1693

—

159

1706

101

145

1584

217

119

1305

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

1.8e-01

9.8e-01

2.3e+00

—

2.2e+00

1.1e+00

4.8e-01

cases:19.08%

controls:16.41%

cases:21.39%

controls:9.29%

cases:9.83%

controls:1.05%

—

cases:7.51%

controls:0.93%

cases:24.12%

controls:9.91%

cases:32.47%

controls:23.00%

281

140

1431

159

136

1553

156

1694

—

160

1696

167

129

1518

350

104

1172

pantoprazole; oral, parenteral
A02BC02 [21600097]

7.2e-01

1.0e+00

—

2.1e+00

1.2e+00

9.8e-01

cases:20.81%

controls:11.33%

cases:15.03%

controls:6.13%

cases:3.47%

controls:1.29%

—

cases:8.67%

controls:1.17%

cases:17.65%

controls:6.29%

cases:28.57%

controls:13.07%

194

137

1518

105

147

1607

167

1690

—

158

1692

106

140

1579

199

110

1323

Case Management Agency
251B00000X [38004193]

2.9e-01

3.5e-01

7.2e-01

3.5e+00

7.7e-01

6.0e-01

4.0e-01

cases:52.02%

controls:44.68%

cases:47.98%

controls:39.31%

cases:26.01%

controls:14.66%

cases:21.39%

controls:0.82%

cases:27.75%

controls:15.13%

cases:55.29%

controls:40.42%

cases:68.18%

controls:59.07%

765

947

673

1039

251

128

1461

136

1698

259

125

1453

681

1004

105

899

623

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

1.5e-01

7.0e-01

1.4e+00

—

2.4e+00

8.5e-01

4.6e-01

cases:21.39%

controls:19.04%

cases:19.65%

controls:10.81%

cases:9.25%

controls:2.45%

—

cases:10.40%

controls:1.05%

cases:24.12%

controls:11.99%

cases:33.77%

controls:24.38%

326

136

1386

185

139

1527

157

1670

—

155

1694

202

129

1483

371

102

1151

Pharmacy visit
OMOP4822462 [581458]

2.0e-01

7.3e-01

7.4e-01

2.0e+00

8.7e-01

8.6e-01

5.2e-01

cases:84.97%

controls:82.24%

cases:83.82%

controls:71.32%

cases:50.87%

controls:33.00%

cases:11.56%

controls:1.69%

cases:56.65%

controls:35.40%

cases:84.71%

controls:70.03%

cases:90.91%

controls:85.61%

147

1408

304

145

1221

491

565

1147

153

1683

606

1106

144

1180

505

140

1303

219

pH of Serum or Plasma
2753-2 [3018418]

6.5e-01

1.0e+00

2.5e+00

—

1.4e+00

1.2e+00

cases:6.94%

controls:3.74%

cases:4.62%

controls:1.75%

cases:3.47%

controls:0.29%

—

cases:7.06%

controls:1.84%

cases:13.64%

controls:4.66%

161

1648

165

1682

167

1707

—

158

1654

133

1451

Laboratory Visit
OMOP4822461 [32036]

3.3e-02

2.4e-01

1.2e+00

2.6e+00

1.2e+00

3.8e-01

1.1e-01

cases:27.17%

controls:26.52%

cases:30.06%

controls:25.35%

cases:20.81%

controls:7.54%

cases:5.20%

controls:0.41%

cases:18.50%

controls:6.54%

cases:34.71%

controls:26.59%

cases:42.21%

controls:39.49%

454

126

1258

434

121

1278

129

137

1583

164

1705

112

141

1600

448

111

1237

601

921

Perimetry
XCK00 [2001301380]

2.2e+00

—

2.5e+00

cases:3.47%

controls:0.41%

—

cases:5.19%

controls:0.46%

167

1705

—

146

1515

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

5.6e-01

1.0e+00

2.0e+00

—

1.8e+00

1.3e+00

1.2e+00

cases:9.25%

controls:5.49%

cases:6.94%

controls:2.63%

cases:3.47%

controls:0.47%

—

cases:2.89%

controls:0.47%

cases:9.41%

controls:2.67%

cases:18.83%

controls:6.70%

157

1618

161

1667

167

1704

—

168

1704

154

1640

102

125

1420

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

1.3e-01

5.9e-01

1.8e+00

—

1.6e+00

9.5e-01

4.2e-01

cases:21.97%

controls:19.86%

cases:22.54%

controls:13.90%

cases:15.03%

controls:2.98%

—

cases:10.40%

controls:2.34%

cases:31.76%

controls:15.25%

cases:38.31%

controls:28.98%

340

135

1372

238

134

1474

147

1661

—

155

1672

257

116

1428

441

1081

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

1.2e-01

5.8e-01

1.7e+00

—

1.6e+00

9.4e-01

4.2e-01

cases:21.97%

controls:19.92%

cases:22.54%

controls:13.96%

cases:15.03%

controls:3.10%

—

cases:10.40%

controls:2.39%

cases:31.76%

controls:15.43%

cases:38.31%

controls:28.91%

341

135

1371

239

134

1473

147

1659

—

155

1671

260

116

1425

440

1082

Ophthalmology
18 [38004463]

7.2e-01

1.1e+00

—

1.4e+00

1.5e+00

7.7e-01

cases:20.23%

controls:10.98%

cases:13.87%

controls:5.14%

—

cases:4.05%

controls:1.05%

cases:18.24%

controls:4.75%

cases:22.73%

controls:11.96%

188

138

1524

149

1624

—

166

1694

139

1605

182

119

1340

Thorax X-ray examination
GD1AA [2001303617]

4.6e-01

1.7e+00

—

1.5e+00

8.9e-01

cases:8.67%

controls:5.67%

cases:7.51%

controls:1.52%

—

cases:5.88%

controls:1.36%

cases:12.99%

controls:5.78%

158

1615

160

1686

—

160

1662

134

1434

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

2.9e-01

5.5e-01

1.3e+00

—

1.9e+00

8.2e-01

1.2e-01

cases:21.39%

controls:16.88%

cases:20.81%

controls:13.20%

cases:9.25%

controls:2.75%

—

cases:12.72%

controls:2.10%

cases:26.47%

controls:13.71%

cases:28.57%

controls:26.15%

289

136

1423

226

137

1486

157

1665

—

151

1676

231

125

1454

398

110

1124

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

2.0e-01

3.1e-01

1.4e+00

—

1.8e+00

7.7e-01

3.4e-01

cases:18.50%

controls:15.65%

cases:16.76%

controls:12.85%

cases:9.83%

controls:2.63%

—

cases:12.14%

controls:2.22%

cases:24.12%

controls:12.82%

cases:30.52%

controls:23.85%

268

141

1444

220

144

1492

156

1667

—

152

1674

216

129

1469

363

107

1159

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

9.5e-02

4.5e-01

1.6e+00

—

1.6e+00

7.6e-01

3.1e-01

cases:23.70%

controls:22.02%

cases:24.86%

controls:17.46%

cases:16.76%

controls:4.03%

—

cases:13.87%

controls:3.04%

cases:32.35%

controls:18.28%

cases:39.61%

controls:32.52%

377

132

1335

299

130

1413

144

1643

—

149

1660

308

115

1377

495

1027

Inpatient Visit
IP [9201]

5.6e-01

1.3e+00

—

1.0e+50

1.8e+00

1.6e+00

9.9e-01

cases:12.72%

controls:7.65%

cases:10.40%

controls:2.98%

—

cases:10.98%

controls:0.00%

cases:2.89%

controls:0.47%

cases:11.76%

controls:2.67%

cases:19.48%

controls:8.21%

131

151

1581

155

1661

—

154

1712

168

1704

150

1640

125

124

1397

Headache
R51.80 [2000503603]

2.2e+00

—

2.3e+00

1.7e+00

cases:8.09%

controls:0.99%

—

cases:2.94%

controls:0.30%

cases:5.84%

controls:1.12%

159

1695

—

165

1680

145

1505

Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]

—

1.0e+50

—

3.8e+00

—

cases:5.78%

controls:0.00%

—

cases:15.58%

controls:0.39%

—

163

1712

—

130

1516

Otolaryngology
4 [38004449]

8.0e-01

1.6e+00

1.9e+00

—

1.4e+00

7.6e-01

cases:18.50%

controls:9.29%

cases:12.72%

controls:2.98%

cases:3.47%

controls:0.53%

—

cases:10.59%

controls:2.73%

cases:16.23%

controls:8.34%

159

141

1553

151

1661

167

1703

—

152

1639

127

129

1395

INR in Blood by Coagulation assay
34714-6 [3032080]

1.0e-01

1.1e+00

1.4e+00

—

2.5e+00

1.1e+00

6.9e-01

cases:6.36%

controls:5.78%

cases:7.51%

controls:2.57%

cases:2.89%

controls:0.76%

—

cases:3.47%

controls:0.29%

cases:7.06%

controls:2.49%

cases:11.69%

controls:6.24%

162

1613

160

1668

168

1699

—

167

1707

158

1643

136

1427

Emergency Room Visit
ER [9203]

3.7e-01

1.2e+00

1.5e+00

1.0e+50

1.2e+00

6.5e-01

7.5e-01

cases:36.42%

controls:28.33%

cases:24.86%

controls:8.82%

cases:5.20%

controls:1.23%

cases:8.09%

controls:0.00%

cases:3.47%

controls:1.11%

cases:16.47%

controls:9.32%

cases:39.61%

controls:23.59%

485

110

1227

151

130

1561

164

1691

159

1712

167

1693

157

142

1528

359

1163

venlafaxine; oral
N06AX16 [21604745]

7.7e-01

1.5e+00

—

1.6e+00

1.8e+00

cases:3.47%

controls:1.64%

cases:3.47%

controls:0.82%

—

cases:4.71%

controls:0.95%

cases:9.09%

controls:1.64%

167

1684

167

1698

—

162

1669

140

1497

MCH [Entitic mass]
28539-5 [3035941]

1.5e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.1e-01

cases:26.59%

controls:23.83%

cases:26.59%

controls:19.68%

cases:13.29%

controls:4.32%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.24%

cases:40.26%

controls:35.41%

408

127

1304

337

127

1375

150

1638

—

147

1651

341

115

1344

539

983

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

1.4e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.0e-01

cases:26.59%

controls:23.89%

cases:26.59%

controls:19.74%

cases:13.29%

controls:4.38%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.24%

cases:40.26%

controls:35.55%

409

127

1303

338

127

1374

150

1637

—

147

1651

341

115

1344

541

981

Platelets [#/volume] in Blood
26515-7 [3007461]

1.5e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.0e-01

cases:26.59%

controls:23.77%

cases:26.59%

controls:19.74%

cases:13.29%

controls:4.38%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.24%

cases:40.26%

controls:35.48%

407

127

1305

338

127

1374

150

1637

—

147

1651

341

115

1344

540

982

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

1.4e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.0e-01

cases:26.59%

controls:23.89%

cases:26.59%

controls:19.68%

cases:13.29%

controls:4.38%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.24%

cases:40.26%

controls:35.55%

409

127

1303

337

127

1375

150

1637

—

147

1651

341

115

1344

541

981

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

5.5e-02

4.6e-01

1.4e+00

—

1.3e+00

7.2e-01

4.3e-01

cases:15.61%

controls:14.89%

cases:18.50%

controls:12.50%

cases:10.98%

controls:2.98%

—

cases:7.51%

controls:2.16%

cases:24.71%

controls:13.83%

cases:32.47%

controls:23.78%

255

146

1457

214

141

1498

154

1661

—

160

1675

233

128

1452

362

104

1160

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

1.4e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.1e-01

cases:26.59%

controls:23.89%

cases:26.59%

controls:19.68%

cases:13.29%

controls:4.38%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.30%

cases:40.26%

controls:35.41%

409

127

1303

337

127

1375

150

1637

—

147

1651

342

115

1343

539

983

Leukocytes [#/volume] in Blood
26464-8 [3010813]

1.4e-01

3.9e-01

1.2e+00

—

1.6e+00

6.2e-01

2.0e-01

cases:26.59%

controls:23.89%

cases:26.59%

controls:19.68%

cases:13.29%

controls:4.38%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.47%

cases:40.26%

controls:35.48%

409

127

1303

337

127

1375

150

1637

—

147

1651

345

115

1340

540

982

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

1.4e-01

3.9e-01

1.2e+00

—

1.6e+00

6.3e-01

2.0e-01

cases:26.59%

controls:23.95%

cases:26.59%

controls:19.74%

cases:13.29%

controls:4.44%

—

cases:15.03%

controls:3.56%

cases:32.35%

controls:20.36%

cases:40.26%

controls:35.55%

410

127

1302

338

127

1374

150

1636

—

147

1651

343

115

1342

541

981

CBC panel - Blood by Automated count
58410-2 [40761511]

4.6e-02

2.1e-01

1.2e+00

—

1.4e+00

7.2e-01

1.8e-01

cases:21.39%

controls:20.62%

cases:16.76%

controls:14.02%

cases:7.51%

controls:2.39%

—

cases:7.51%

controls:2.04%

cases:23.53%

controls:13.06%

cases:31.82%

controls:28.12%

353

136

1359

240

144

1472

160

1671

—

160

1677

220

130

1465

428

105

1094

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

2.3e-01

9.0e-01

1.6e+00

—

2.3e+00

7.6e-01

8.5e-01

cases:9.25%

controls:7.48%

cases:8.09%

controls:3.45%

cases:3.47%

controls:0.70%

—

cases:3.47%

controls:0.35%

cases:8.82%

controls:4.33%

cases:20.78%

controls:10.05%

128

157

1584

159

1653

167

1700

—

167

1706

155

1612

153

122

1369

Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]

1.8e-01

1.5e+00

—

1.6e+00

5.3e-01

cases:3.47%

controls:2.92%

cases:5.20%

controls:1.17%

—

cases:5.29%

controls:1.13%

cases:6.49%

controls:3.94%

167

1662

164

1692

—

161

1666

144

1462

Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]

2.9e-01

8.0e-01

—

2.0e+00

1.0e+00

4.7e-01

cases:12.14%

controls:9.40%

cases:8.09%

controls:3.80%

—

cases:5.20%

controls:0.70%

cases:11.18%

controls:4.27%

cases:16.88%

controls:11.30%

161

152

1551

159

1647

—

164

1700

151

1613

172

128

1350

Office Visit
OMOP4822458 [581477]

7.0e-01

7.8e-01

—

1.0e+50

—

1.7e+00

1.3e+00

cases:14.45%

controls:7.77%

cases:5.20%

controls:2.45%

—

cases:2.89%

controls:0.00%

—

cases:8.82%

controls:1.78%

cases:16.23%

controls:4.93%

133

148

1579

164

1670

—

168

1712

—

155

1655

129

1447

androstanolone
A14AA01 [21600917]

2.8e+00

—

cases:6.94%

controls:0.47%

—

161

1704

—

androstanolone
G03BB02 [21602513]

2.8e+00

—

cases:6.94%

controls:0.47%

—

161

1704

—

Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]

—

1.0e+50

—

2.7e+00

1.6e+00

—

cases:5.20%

controls:0.00%

—

cases:5.29%

controls:0.36%

cases:4.55%

controls:0.99%

—

164

1712

—

161

1679

147

1507

Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]

3.6e-01

8.3e-01

—

1.8e+00

9.1e-01

5.4e-01

cases:14.45%

controls:10.51%

cases:9.83%

controls:4.56%

—

cases:4.05%

controls:0.70%

cases:11.18%

controls:4.81%

cases:18.18%

controls:11.50%

180

148

1532

156

1634

—

166

1700

151

1604

175

126

1347

Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]

—

2.5e+00

2.1e+00

—

cases:3.53%

controls:0.30%

cases:3.25%

controls:0.39%

—

164

1680

149

1516

Inpatient Hospital
21 [8717]

3.5e-01

1.2e+00

1.4e+00

1.0e+50

1.2e+00

6.1e-01

cases:34.10%

controls:26.69%

cases:23.12%

controls:7.94%

cases:5.20%

controls:1.29%

cases:6.94%

controls:0.00%

cases:3.47%

controls:1.05%

cases:21.76%

controls:7.89%

cases:31.82%

controls:20.24%

457

114

1255

136

133

1576

164

1690

161

1712

167

1694

133

1552

308

105

1214

Outpatient Hospital
22 [8756]

4.4e-01

1.3e+00

—

1.2e+00

4.9e-01

cases:28.32%

controls:20.33%

cases:17.92%

controls:5.84%

cases:4.05%

controls:1.17%

—

cases:16.47%

controls:5.82%

cases:24.03%

controls:16.23%

348

124

1364

100

142

1612

166

1692

—

142

1587

247

117

1275

More than one and less than three hours
ZXE10 [2001311401]

6.3e-01

1.5e+00

—

2.4e+00

-1.2e-02

cases:7.51%

controls:4.15%

cases:3.47%

controls:0.82%

—

cases:7.65%

controls:0.77%

cases:3.25%

controls:3.29%

160

1641

167

1698

—

157

1672

149

1472

Gastroenterology
10 [38004455]

9.4e-01

1.1e+00

—

1.3e+00

1.0e+00

cases:8.09%

controls:3.33%

cases:5.78%

controls:1.99%

—

cases:6.47%

controls:1.78%

cases:11.69%

controls:4.60%

159

1655

163

1678

—

159

1655

136

1452

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

1.9e-01

6.1e-01

1.3e+00

—

1.5e+00

8.0e-01

5.7e-01

cases:14.45%

controls:12.27%

cases:12.72%

controls:7.36%

cases:5.20%

controls:1.46%

—

cases:5.20%

controls:1.17%

cases:14.71%

controls:7.18%

cases:24.03%

controls:15.11%

210

148

1502

126

151

1586

164

1687

—

164

1692

121

145

1564

230

117

1292

alendronic acid; oral
M05BA04 [21604152]

1.2e+00

—

1.5e+00

2.3e+00

cases:2.89%

controls:0.88%

—

cases:2.94%

controls:0.65%

cases:4.55%

controls:0.46%

168

1697

—

165

1674

147

1515

Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]

—

2.3e+00

1.8e+00

—

cases:3.53%

controls:0.36%

cases:3.90%

controls:0.66%

—

164

1679

148

1512

Examination of eyes and vision
Z01.0 [45566391]

6.2e-01

—

2.3e+00

7.3e-01

cases:2.89%

controls:1.58%

—

cases:3.53%

controls:0.36%

cases:4.55%

controls:2.23%

168

1685

—

164

1679

147

1488

Emergency Medicine
93 [38004510]

-1.7e-01

5.3e-01

1.8e+00

—

2.2e+00

7.3e-01

5.0e-01

cases:8.67%

controls:10.11%

cases:7.51%

controls:4.56%

cases:3.47%

controls:0.58%

—

cases:4.05%

controls:0.47%

cases:8.24%

controls:4.15%

cases:19.48%

controls:12.81%

173

158

1539

160

1634

167

1702

—

166

1704

156

1615

195

124

1327

Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]

—

2.2e+00

—

cases:3.90%

controls:0.46%

—

148

1515

Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]

2.2e+00

—

1.0e+50

—

cases:3.47%

controls:0.41%

—

cases:4.05%

controls:0.00%

—

167

1705

—

166

1712

—

Scheduled procedure
ZXD10 [2001311387]

6.4e-01

1.2e+00

—

2.1e+00

4.1e-01

cases:8.67%

controls:4.79%

cases:3.47%

controls:1.05%

—

cases:7.06%

controls:0.95%

cases:5.84%

controls:3.94%

158

1630

167

1694

—

158

1669

145

1462

Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]

-7.5e-03

4.5e-01

—

2.0e+00

6.6e-01

2.2e-01

cases:14.45%

controls:14.54%

cases:15.03%

controls:10.11%

—

cases:4.62%

controls:0.64%

cases:18.82%

controls:10.68%

cases:27.92%

controls:23.72%

249

148

1463

173

147

1539

—

165

1701

180

138

1505

361

111

1161

Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]

6.6e-01

—

1.9e+00

9.1e-01

cases:2.89%

controls:1.52%

—

cases:4.12%

controls:0.65%

cases:5.84%

controls:2.43%

168

1686

—

163

1674

145

1485

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]

—

1.8e+00

—

cases:4.55%

controls:0.79%

—

147

1510

Calprotectin [Mass/mass] in Stool
38445-3 [3048689]

—

1.8e+00

5.5e-01

—

cases:4.12%

controls:0.71%

cases:3.25%

controls:1.91%

—

163

1673

149

1493

Osmolality of Urine
2695-5 [3026782]

3.4e-01

1.8e+00

—

1.4e+00

5.2e-01

cases:4.05%

controls:2.92%

cases:4.62%

controls:0.82%

—

cases:3.53%

controls:0.89%

cases:4.55%

controls:2.76%

166

1662

165

1698

—

164

1670

147

1480

Obstetrics / Gynecology
16 [38004461]

3.3e-01

7.9e-01

—

1.0e+50

—

1.0e+00

7.1e-01

cases:20.23%

controls:15.48%

cases:11.56%

controls:5.61%

—

cases:5.78%

controls:0.00%

—

cases:14.12%

controls:5.46%

cases:24.03%

controls:13.40%

265

138

1447

153

1616

—

163

1712

—

146

1593

204

117

1318

Supplier / Service Provider
OMOP5117446 [33004]

-1.2e+00

—

2.9e+00

cases:9.83%

controls:26.64%

—

cases:12.99%

controls:0.79%

456

156

1256

—

134

1510

Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]

—

-1.0e+50

—

1.7e+00

—

cases:0.00%

controls:0.35%

—

cases:5.19%

controls:0.99%

—

173

1706

—

146

1507

Urinary tract infection, site not specified
N39.0 [45548665]

1.7e+00

—

1.8e+00

5.5e-01

cases:4.62%

controls:0.88%

—

cases:2.94%

controls:0.47%

cases:3.25%

controls:1.91%

165

1697

—

165

1677

149

1493

Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]

7.7e-01

1.7e+00

—

7.3e-01

cases:6.94%

controls:3.33%

cases:5.20%

controls:0.99%

—

cases:5.84%

controls:2.89%

161

1655

164

1695

—

145

1478

Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]

—

1.6e+00

—

cases:5.19%

controls:1.05%

—

146

1506

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

—

6.6e-01

-1.0e+50

—

1.6e+00

9.3e-01

—

cases:2.89%

controls:1.52%

cases:0.00%

controls:0.29%

—

cases:5.88%

controls:1.25%

cases:9.74%

controls:4.07%

—

168

1686

173

1707

—

160

1664

139

1460

Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]

5.0e-01

—

1.2e+00

1.5e+00

cases:4.62%

controls:2.86%

—

cases:2.94%

controls:0.89%

cases:7.79%

controls:1.77%

165

1663

—

165

1670

142

1495

Gynaecological examination (general)(routine)
Z01.4 [45542395]

1.5e+00

—

1.3e+00

cases:5.20%

controls:1.23%

—

cases:3.90%

controls:1.05%

164

1691

—

148

1506

General anesthesia, balanced
WX408 [2001310808]

4.9e-01

—

1.5e+00

cases:4.05%

controls:2.51%

—

cases:6.49%

controls:1.58%

166

1669

—

144

1498

Sleep apnoea
G47.3 [45562094]

7.3e-01

6.3e-01

—

1.4e+00

9.1e-01

cases:6.36%

controls:3.15%

cases:3.47%

controls:1.87%

—

cases:7.65%

controls:1.96%

cases:9.09%

controls:3.88%

162

1658

167

1680

—

157

1652

140

1463

Prothrombin time (PT) actual/Normal
5894-1 [3033658]

2.2e-01

1.2e+00

—

1.4e+00

6.3e-01

cases:3.47%

controls:2.80%

cases:4.62%

controls:1.46%

—

cases:5.88%

controls:1.54%

cases:7.14%

controls:3.94%

167

1664

165

1687

—

160

1659

143

1462

Other specified counselling
Z71.8 [45581061]

—

7.4e-01

—

1.4e+00

4.7e-01

—

cases:2.89%

controls:1.40%

—

cases:5.88%

controls:1.54%

cases:7.79%

controls:4.99%

—

168

1688

—

160

1659

142

1446

Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]

4.0e-01

—

1.1e+00

1.3e+00

cases:4.05%

controls:2.75%

—

cases:2.94%

controls:1.01%

cases:9.74%

controls:2.89%

166

1665

—

165

1668

139

1478

pregabalin; oral
N02BF02 [955152]

7.2e-01

1.0e+00

—

-1.0e+50

7.0e-01

1.3e+00

cases:6.36%

controls:3.21%

cases:4.05%

controls:1.52%

—

cases:0.00%

controls:0.41%

cases:2.94%

controls:1.48%

cases:9.09%

controls:2.76%

162

1657

166

1686

—

173

1705

165

1660

140

1480

Treatment plan or consultation
WZC00 [2001310885]

9.9e-02

—

1.1e+00

1.2e+00

cases:4.62%

controls:4.21%

—

cases:4.71%

controls:1.54%

cases:13.64%

controls:4.34%

165

1640

—

162

1659

133

1456

Dental calculus supragingival
K03.64 [2000502689]

4.6e-01

1.0e+00

—

1.2e+00

cases:4.62%

controls:2.98%

cases:2.89%

controls:1.05%

—

cases:12.34%

controls:3.94%

165

1661

168

1694

—

135

1462

calcium (different salts in combination); oral
A12AA20 [21600872]

6.6e-01

8.7e-01

—

1.3e+00

7.4e-01

1.2e+00

cases:10.40%

controls:5.67%

cases:10.98%

controls:4.91%

—

cases:5.20%

controls:1.52%

cases:10.00%

controls:5.04%

cases:18.83%

controls:6.50%

155

1615

154

1628

—

164

1686

153

1600

125

1423

Physical Medicine And Rehabilitation
25 [38004468]

6.1e-01

6.3e-01

—

5.7e-01

1.2e+00

cases:10.40%

controls:5.96%

cases:3.47%

controls:1.87%

—

cases:4.12%

controls:2.37%

cases:11.69%

controls:3.94%

102

155

1610

167

1680

—

163

1645

136

1462

Upper gastrointestinal surgery
106 [44777669]

5.4e-01

8.0e-01

—

1.2e+00

6.7e-01

cases:9.83%

controls:5.96%

cases:5.20%

controls:2.39%

—

cases:8.24%

controls:2.73%

cases:13.64%

controls:7.49%

102

156

1610

164

1671

—

156

1639

114

133

1408

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

7.7e-01

5.1e-01

—

1.1e+00

cases:9.83%

controls:4.79%

cases:3.47%

controls:2.10%

—

cases:13.64%

controls:4.80%

156

1630

167

1676

—

133

1449

amitriptyline; oral, parenteral
N06AA09 [21604696]

8.7e-01

6.7e-01

-1.0e+50

—

1.1e+00

cases:6.94%

controls:3.04%

cases:3.47%

controls:1.81%

cases:0.00%

controls:0.35%

—

cases:9.74%

controls:3.35%

161

1660

167

1681

173

1706

—

139

1471

Chronic apical periodontitis
K04.5 [45586691]

2.4e-01

—

1.1e+00

cases:3.47%

controls:2.75%

—

cases:9.09%

controls:3.15%

167

1665

—

140

1474

Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]

1.1e+00

—

1.0e+00

6.1e-01

cases:9.25%

controls:3.21%

—

cases:2.94%

controls:1.07%

cases:5.19%

controls:2.89%

157

1657

—

165

1667

146

1478

Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]

5.9e-02

6.7e-01

—

9.2e-01

1.1e+00

cases:6.36%

controls:6.02%

cases:3.47%

controls:1.81%

—

cases:5.88%

controls:2.43%

cases:15.58%

controls:5.98%

103

162

1609

167

1681

—

160

1644

130

1431

Pulmonary Disease
29 [38004472]

7.8e-01

4.7e-01

—

7.8e-01

1.1e+00

cases:13.87%

controls:6.89%

cases:5.20%

controls:3.33%

—

cases:5.88%

controls:2.79%

cases:16.23%

controls:6.31%

118

149

1594

164

1655

—

160

1638

129

1426

Differential panel, method unspecified - Blood
69738-3 [42870588]

8.5e-02

3.1e-01

—

8.2e-01

1.1e+00

cases:4.62%

controls:4.26%

cases:3.47%

controls:2.57%

—

cases:6.47%

controls:2.97%

cases:11.04%

controls:4.14%

165

1639

167

1668

—

159

1635

137

1459

lansoprazole; oral
A02BC03 [21600098]

1.0e+00

—

1.3e+00

8.0e-01

cases:9.25%

controls:3.45%

cases:5.20%

controls:1.93%

—

cases:5.29%

controls:1.54%

cases:7.14%

controls:3.35%

157

1653

164

1679

—

161

1659

143

1471

Eosinophils/Leukocytes in Blood
26450-7 [3006504]

-3.2e-02

5.9e-01

—

8.1e-01

1.0e+00

cases:5.78%

controls:5.96%

cases:6.94%

controls:3.97%

—

cases:10.00%

controls:4.69%

cases:18.83%

controls:7.69%

102

163

1610

161

1644

—

153

1606

117

125

1405

Neutrophils/Leukocytes in Blood
26511-6 [3018010]

-2.2e-02

6.0e-01

—

6.8e-01

1.0e+00

cases:5.78%

controls:5.90%

cases:6.94%

controls:3.91%

—

cases:8.82%

controls:4.69%

cases:18.83%

controls:7.69%

101

163

1611

161

1645

—

155

1606

117

125

1405

Lymphocytes/Leukocytes in Blood
26478-8 [3002030]

-5.3e-02

5.9e-01

—

7.2e-01

1.0e+00

cases:5.78%

controls:6.07%

cases:6.94%

controls:3.97%

—

cases:9.41%

controls:4.81%

cases:19.48%

controls:8.02%

104

163

1608

161

1644

—

154

1604

122

124

1400

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

4.1e-02

5.3e-01

—

1.4e+00

8.6e-01

1.0e+00

cases:8.67%

controls:8.35%

cases:8.09%

controls:4.91%

—

cases:2.89%

controls:0.76%

cases:12.35%

controls:5.64%

cases:22.08%

controls:9.26%

143

158

1569

159

1628

—

168

1699

149

1590

141

120

1381

Monocytes/Leukocytes in Blood
26485-3 [3019069]

-3.2e-02

6.0e-01

—

8.1e-01

1.0e+00

cases:5.78%

controls:5.96%

cases:6.94%

controls:3.91%

—

cases:10.00%

controls:4.69%

cases:18.83%

controls:7.75%

102

163

1610

161

1645

—

153

1606

118

125

1404

Basophils/Leukocytes in Blood
30180-4 [3022096]

-2.2e-02

6.0e-01

—

8.3e-01

9.8e-01

cases:5.78%

controls:5.90%

cases:6.94%

controls:3.91%

—

cases:10.00%

controls:4.63%

cases:18.18%

controls:7.69%

101

163

1611

161

1645

—

153

1607

117

126

1405

Lymphocytes [#/volume] in Blood
26474-7 [3019198]

7.2e-02

7.1e-01

—

7.0e-01

9.5e-01

cases:6.94%

controls:6.48%

cases:8.09%

controls:4.15%

—

cases:9.41%

controls:4.93%

cases:19.48%

controls:8.54%

111

161

1601

159

1641

—

154

1602

130

124

1392

Eosinophils [#/volume] in Blood
26449-9 [3013115]

8.4e-02

6.8e-01

—

7.0e-01

9.5e-01

cases:7.51%

controls:6.95%

cases:8.09%

controls:4.26%

—

cases:9.41%

controls:4.93%

cases:19.48%

controls:8.54%

119

160

1593

159

1639

—

154

1602

130

124

1392

Essential (primary) hypertension
I10 [45591453]

4.1e-01

9.4e-01

—

1.0e+50

—

6.0e-01

5.6e-01

cases:12.72%

controls:8.82%

cases:10.40%

controls:4.32%

—

cases:2.89%

controls:0.00%

—

cases:9.41%

controls:5.40%

cases:20.78%

controls:13.01%

151

1561

155

1638

—

168

1712

—

154

1594

198

122

1324

Basophils [#/volume] in Blood
26444-0 [3006315]

1.1e-01

7.4e-01

—

7.3e-01

9.4e-01

cases:6.94%

controls:6.25%

cases:8.09%

controls:4.03%

—

cases:9.41%

controls:4.75%

cases:18.83%

controls:8.28%

107

161

1605

159

1643

—

154

1605

126

125

1396

zopiclone; oral
N05CF01 [21604654]

9.4e-01

5.4e-01

—

5.6e-01

5.1e-01

cases:11.56%

controls:4.85%

cases:5.20%

controls:3.10%

—

cases:5.29%

controls:3.09%

cases:9.09%

controls:5.65%

153

1629

164

1659

—

161

1633

140

1436

Psychiatry
26 [38004469]

6.4e-01

8.8e-01

9.2e-01

—

9.1e-01

9.4e-01

cases:9.83%

controls:5.43%

cases:6.36%

controls:2.75%

cases:2.89%

controls:1.17%

—

cases:7.06%

controls:2.97%

cases:12.99%

controls:5.52%

156

1619

162

1665

168

1692

—

158

1635

134

1438

Monocytes [#/volume] in Blood
26484-6 [3001604]

1.1e-01

7.4e-01

—

7.2e-01

9.1e-01

cases:6.94%

controls:6.25%

cases:8.09%

controls:4.03%

—

cases:9.41%

controls:4.81%

cases:18.18%

controls:8.21%

107

161

1605

159

1643

—

154

1604

125

126

1397

azithromycin; oral, parenteral
J01FA10 [21602978]

9.0e-01

6.6e-01

—

6.0e-01

4.6e-01

cases:20.23%

controls:9.35%

cases:2.89%

controls:1.52%

—

cases:3.53%

controls:1.96%

cases:11.69%

controls:7.69%

160

138

1552

168

1686

—

164

1652

117

136

1405

Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]

4.6e-01

8.2e-01

—

9.7e-01

8.9e-01

cases:8.09%

controls:5.26%

cases:5.78%

controls:2.63%

—

cases:7.06%

controls:2.79%

cases:14.94%

controls:6.70%

159

1622

163

1667

—

158

1638

102

131

1420

12 lead EKG panel
34534-8 [3044889]

4.0e-01

6.6e-01

—

8.8e-01

4.3e-01

cases:14.45%

controls:10.16%

cases:8.67%

controls:4.67%

—

cases:11.76%

controls:5.22%

cases:20.13%

controls:14.06%

174

148

1538

158

1632

—

150

1597

214

123

1308

amlodipine; oral
C08CA01 [21601747]

-5.7e-02

-7.5e-02

—

1.5e-01

8.4e-01

cases:5.20%

controls:5.49%

cases:4.62%

controls:4.96%

—

cases:5.88%

controls:5.10%

cases:14.94%

controls:7.03%

164

1618

165

1627

—

160

1599

107

131

1415

Two-surface restoration
SFA20 [2001310359]

1.4e-01

-3.0e-01

—

2.3e-01

7.8e-01

cases:11.56%

controls:10.16%

cases:3.47%

controls:4.61%

—

cases:5.88%

controls:4.75%

cases:24.03%

controls:12.68%

174

153

1538

167

1633

—

160

1605

193

117

1329

Infiltration anesthesia
WX110 [2001310767]

2.0e-01

6.2e-01

—

5.4e-01

7.0e-01

cases:15.03%

controls:12.68%

cases:8.67%

controls:4.85%

—

cases:8.82%

controls:5.34%

cases:27.27%

controls:15.70%

217

147

1495

158

1629

—

155

1595

239

112

1283

tizanidine; oral
M03BX02 [21604116]

6.9e-01

6.5e-01

—

2.7e-01

4.8e-01

cases:22.54%

controls:12.79%

cases:8.09%

controls:4.38%

—

cases:5.29%

controls:4.09%

cases:16.88%

controls:11.17%

219

134

1493

159

1637

—

161

1616

170

128

1352

Extensive health check-up on eighth grade
SPAT1386 [2001700486]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

154

1510

Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.47%

—

cases:0.00%

controls:0.30%

cases:0.00%

controls:0.46%

173

1704

—

170

1680

154

1515

Balloon angioplasty, including several vessels
AN2 [2000200164]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

No procedures
SPAT1301 [2001700402]

1.9e-01

7.0e-01

—

-1.0e+50

—

4.9e-01

cases:4.62%

controls:3.86%

cases:3.47%

controls:1.75%

—

cases:0.00%

controls:0.35%

—

cases:5.84%

controls:3.68%

165

1646

167

1682

—

173

1706

—

145

1466

formoterol and budesonide
R03AK07 [21603281]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.82%

—

cases:0.00%

controls:0.53%

—

173

1698

—

170

1676

—

Albumin [Presence] in Urine by Test strip
50949-7 [3029937]

—

4.5e-01

—

3.8e-01

—

cases:2.89%

controls:1.87%

—

cases:7.79%

controls:5.45%

—

168

1680

—

142

1439

Dentistry
C5 [903277]

—

-1.0e+50

—

8.7e-01

—

cases:0.00%

controls:0.93%

—

cases:5.19%

controls:2.23%

—

173

1696

—

146

1488

Radiculopathy
M54.1 [45577287]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

154

1515

Chloride [Moles/volume] in Blood
2069-3 [3018572]

—

-1.0e+50

—

cases:0.00%

controls:0.39%

—

154

1516

Free T4 and TSH panel - Serum or Plasma
24348-5 [3001019]

—

-1.0e+50

—

cases:0.00%

controls:0.99%

—

154

1507

Infective dermatitis
L30.3 [45577034]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Other specified pulpit
K04.08 [2000502703]

—

-1.0e+50

—

cases:0.00%

controls:1.45%

—

154

1500

SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]

—

-1.0e+50

—

cases:0.00%

controls:1.29%

—

173

1690

—

Olecranon bursitis
M70.2 [45557961]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Stress incontinence
N39.3 [45539046]

-1.0e+50

—

cases:0.00%

controls:0.29%

cases:0.00%

controls:0.29%

—

173

1707

173

1707

—

plastic IUD with progestogen; implant
G02BA03 [21602449]

3.6e-01

-1.0e+50

—

2.9e-01

cases:4.05%

controls:2.86%

cases:0.00%

controls:0.64%

—

cases:3.90%

controls:2.96%

166

1663

173

1701

—

148

1477

dexamethasone; local oral
A01AC02 [21600035]

—

-1.0e+50

—

cases:0.00%

controls:0.76%

—

173

1699

—

Sensorineural hearing loss, bilateral
H90.3 [45576850]

1.0e+00

1.3e+00

—

1.0e+00

cases:4.62%

controls:1.75%

cases:3.47%

controls:0.99%

—

cases:5.84%

controls:2.23%

165

1682

167

1695

—

145

1488

tacrolimus
D11AH01 [21602338]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

felodipine; oral
C08CA02 [21601748]

—

1.7e+00

—

cases:3.47%

controls:0.64%

—

167

1701

—

Obstetric epidural analgesia
WX307 [2001310797]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.70%

—

cases:0.00%

controls:0.79%

173

1700

—

154

1510

pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]

-1.0e+50

—

cases:0.00%

controls:0.99%

—

173

1695

—

Other migraine
G43.8 [45595941]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]

-1.0e+50

—

cases:0.00%

controls:0.47%

—

173

1704

—

Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Excessive attrition of teeth
K03.0 [45601139]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

ranitidine bismuth citrate; oral
A02BA07 [21600088]

1.1e+00

—

cases:4.05%

controls:1.40%

—

166

1688

—

Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]

-8.3e-02

1.0e+00

—

6.8e-01

2.0e-01

cases:4.05%

controls:4.38%

cases:3.47%

controls:1.29%

—

cases:4.12%

controls:2.14%

cases:6.49%

controls:5.39%

166

1637

167

1690

—

163

1649

144

1440

Provision of support and information to patient’s family members
SPAT1245 [2001700346]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.33%

173

1706

—

154

1517

budesonide; inhalant
R03BA02 [21603285]

4.5e-01

—

1.5e+00

—

4.7e-01

cases:6.36%

controls:4.15%

—

cases:2.89%

controls:0.64%

—

cases:7.14%

controls:4.60%

162

1641

—

168

1701

—

143

1452

Cytology report of Cervical or vaginal smear or scraping Cyto stain
47528-5 [3050380]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.76%

cases:0.00%

controls:0.29%

—

cases:0.00%

controls:0.79%

173

1699

173

1707

—

154

1510

Maternal care for other specified fetal problems
O36.8 [45567946]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Additional procedure necessary for restorative treatment
SFC01 [2001310369]

3.2e-01

-1.0e+50

—

1.8e-01

cases:4.05%

controls:2.98%

cases:0.00%

controls:0.93%

—

cases:3.90%

controls:3.29%

166

1661

173

1696

—

148

1472

Nonorganic insomnia
F51.0 [45552492]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.93%

—

cases:0.00%

controls:0.53%

—

173

1696

—

170

1676

—

finasteride; oral
D11AX10 [21602350]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.88%

cases:0.00%

controls:0.53%

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.35%

cases:0.00%

controls:0.59%

—

173

1697

173

1703

173

1706

—

173

1706

170

1675

—

Fracture of other finger
S62.6 [45564362]

-1.0e+50

—

cases:0.00%

controls:0.47%

—

173

1704

—

Clinic/Center
261Q00000X [38004207]

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

clonazepam; oral, parenteral
N03AE01 [21604415]

1.2e+00

—

1.4e+00

cases:3.47%

controls:1.11%

—

cases:3.25%

controls:0.79%

167

1693

—

149

1510

Bacteria identified in Urine by Culture
630-4 [3026008]

6.8e-01

—

7.8e-01

5.3e-01

cases:6.36%

controls:3.33%

—

cases:2.94%

controls:1.36%

cases:7.14%

controls:4.34%

162

1655

—

165

1662

143

1456

Nail symptom/complaint
S22 [2002000987]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Leukocytes [Presence] in Urine
33052-2 [3045414]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Generalized enlarged lymph nodes
R59.1 [45563318]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Lateral epicondylitis
M77.1 [45572551]

—

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

insulin glargine; parenteral
A10AE04 [21600739]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

173

1704

—

Screening procedure
SPAT1324 [2001700425]

3.6e-01

—

-1.0e+50

—

-1.0e+50

3.4e-01

cases:3.47%

controls:2.45%

—

cases:0.00%

controls:0.29%

—

cases:0.00%

controls:0.89%

cases:4.55%

controls:3.29%

167

1670

—

173

1707

—

170

1670

147

1472

Fracture of tooth root
S02.53 [2000503620]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

oxazepam; oral
N05BA04 [21604569]

5.6e-01

1.1e+00

—

1.1e+00

8.8e-01

cases:5.78%

controls:3.39%

cases:5.20%

controls:1.75%

—

cases:5.88%

controls:2.02%

cases:9.74%

controls:4.27%

163

1654

164

1682

—

160

1651

139

1457

Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]

2.2e-01

2.0e-01

—

1.8e-01

-5.6e-02

cases:19.65%

controls:16.47%

cases:11.56%

controls:9.64%

—

cases:11.18%

controls:9.50%

cases:22.08%

controls:23.06%

282

139

1430

165

153

1547

—

160

151

1525

351

120

1171

Methadone [Presence] in Urine by Screen method
19550-3 [3028707]

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

Erythrocytes [#/volume] in Urine
30391-7 [3002582]

-1.3e-01

1.0e+00

—

6.0e-01

4.9e-01

cases:3.47%

controls:3.91%

cases:4.62%

controls:1.75%

—

cases:3.53%

controls:1.96%

cases:8.44%

controls:5.32%

167

1645

165

1682

—

164

1652

141

1441

Examination and observation for other specified reasons
Z04.8 [45552063]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

cases:0.00%

controls:0.30%

—

173

1703

—

170

1680

—

Presence of coronary angioplasty implant and graft
Z95.5 [45542496]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]

—

6.3e-01

—

cases:3.90%

controls:2.10%

—

148

1490

Acute tonsillitis
J03 [45552876]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]

—

1.6e+00

—

9.1e-01

—

cases:2.89%

controls:0.58%

—

cases:5.84%

controls:2.43%

—

168

1702

—

145

1485

empagliflozin; oral
A10BK03 [1123740]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Open wound of scalp
S01.0 [45592468]

—

-1.0e+50

—

cases:0.00%

controls:0.39%

—

154

1516

Paroxysmal atrial fibrillation
I48.0 [45581776]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

154

1515

Removal of sutures
SPAT1153 [2001700254]

2.4e-01

—

4.5e-01

cases:4.62%

controls:3.68%

—

cases:4.55%

controls:2.96%

165

1649

—

147

1477

Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]

—

-1.0e+50

—

1.7e-02

—

cases:0.00%

controls:0.35%

—

cases:7.14%

controls:7.03%

—

173

1706

—

107

143

1415

tetracycline; oral, parenteral
J01AA07 [21602805]

1.0e+00

—

cases:4.05%

controls:1.46%

—

166

1687

—

Tension-type headache
G44.2 [45581495]

1.7e+00

—

1.1e+00

cases:3.47%

controls:0.64%

—

cases:3.25%

controls:1.12%

167

1701

—

149

1505

Preventive oral health care, extensive
SCA03 [2001310304]

-1.0e+50

—

cases:0.00%

controls:0.53%

—

173

1703

—

Dysthymia
F34.1 [45586238]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Neck ultrasound examination
EP1AE [2001302284]

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]

—

-1.0e+50

—

cases:0.00%

controls:0.39%

—

154

1516

chlorhexidine, combinations
D08AC52 [21602208]

7.6e-01

—

-1.0e+50

—

cases:4.62%

controls:2.22%

—

cases:0.00%

controls:0.77%

—

165

1674

—

170

1672

—

ciclesonide; nasal
R01AD13 [43534836]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]

—

-1.0e+50

—

cases:0.00%

controls:0.85%

—

154

1509

SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

cases:0.00%

controls:0.72%

—

170

1679

154

1511

Urticaria
L50 [45543371]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Diffusion capacity of lung
54715006 [4182985]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Somatotropin [Mass/volume] in Serum or Plasma
2963-7 [3023709]

—

1.0e+50

—

cases:3.53%

controls:0.00%

cases:3.25%

controls:0.00%

—

164

1685

149

1522

Moderate depressive episode with somatic syndrome
F32.11 [2000501981]

-1.0e+50

—

cases:0.00%

controls:0.47%

—

173

1704

—

Musculoskeletal sympt/complt other
L29 [2002000648]

—

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]

—

9.8e-01

—

cases:3.25%

controls:1.25%

—

149

1503

metronidazole; vaginal
G01AF01 [21602392]

1.1e+00

—

6.2e-01

cases:4.62%

controls:1.52%

—

cases:3.25%

controls:1.77%

165

1686

—

149

1495

Single live birth
Z37.0 [45571346]

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

154

1512

Obesity
T82 [2002001125]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

154

1515

Estradiol (E2) [Moles/volume] in Serum or Plasma
14715-7 [3026725]

—

1.0e+50

—

cases:2.89%

controls:0.00%

—

168

1712

—

Leukocytes [#/volume] in Urine
30405-5 [3018095]

2.2e-01

8.7e-01

—

7.3e-01

4.3e-01

cases:5.20%

controls:4.21%

cases:4.62%

controls:1.99%

—

cases:5.29%

controls:2.61%

cases:9.74%

controls:6.57%

164

1640

165

1678

—

161

1641

100

139

1422

nifedipine; oral, parenteral
C08CA05 [21601751]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.59%

—

173

1706

—

154

1513

Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]

-1.0e+50

—

1.2e+00

cases:0.00%

controls:1.23%

—

cases:3.90%

controls:1.25%

173

1691

—

148

1503

memantine; oral
N06DX01 [21604799]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.35%

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.36%

cases:0.00%

controls:0.59%

173

1706

173

1706

—

170

1679

154

1513

cough suppressants and expectorants
R05FB02 [21603442]

8.9e-01

—

cases:4.05%

controls:1.69%

—

166

1683

—

IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.47%

cases:0.00%

controls:0.29%

—

cases:0.00%

controls:0.42%

—

173

1704

173

1707

—

170

1678

—

Anterior pituitary hypofunction
101 [2001600101]

1.0e+50

—

1.0e+50

cases:4.05%

controls:0.00%

—

cases:8.82%

controls:0.00%

cases:3.90%

controls:0.00%

166

1712

—

155

1685

148

1522

Pain, unspecified
R52.9 [45544151]

—

-1.0e+50

—

cases:0.00%

controls:1.05%

—

154

1506

Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.58%

—

cases:0.00%

controls:0.83%

cases:0.00%

controls:1.91%

—

173

1702

—

170

1671

154

1493

Abdominal pain localized other
D06 [2002000305]

-1.0e+50

—

cases:0.00%

controls:0.70%

cases:0.00%

controls:0.41%

—

173

1700

173

1705

—

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

—

1.4e+00

—

1.4e+00

—

cases:2.89%

controls:0.76%

—

cases:3.25%

controls:0.85%

—

168

1699

—

149

1509

potassium chloride; oral
A12BA01 [21600877]

—

1.7e+00

1.4e+00

—

cases:2.94%

controls:0.53%

cases:4.55%

controls:1.18%

—

165

1676

147

1504

Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]

—

-1.0e+50

—

cases:0.00%

controls:0.72%

—

154

1511

Difficulties in perfomrming procedure
ZXD30 [2001311389]

-1.0e+50

—

cases:0.00%

controls:0.41%

—

173

1705

—

Palpitations/awareness of heart
K04 [2002000547]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.58%

—

cases:0.00%

controls:0.33%

173

1702

—

154

1517

Primary gonarthrosis, bilateral
M17.0 [45562648]

—

-1.0e+50

—

cases:0.00%

controls:1.25%

—

154

1503

Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.53%

—

cases:0.00%

controls:0.59%

173

1703

—

154

1513

Support of social functional capacity
SPAT1234 [2001700335]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.39%

173

1706

—

154

1516

Other specified medical care
Z51.88 [2000503765]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Senile incipient cataract
H25.0 [45576699]

—

-1.0e+50

—

cases:0.00%

controls:0.42%

cases:0.00%

controls:0.59%

—

170

1678

154

1513

Abdominal ultrasound examination
JN3AE [2001305555]

—

-1.0e+50

1.2e+00

—

cases:0.00%

controls:0.42%

cases:3.25%

controls:0.99%

—

170

1678

149

1507

cloZAPine [Moles/volume] in Serum or Plasma
14656-3 [3000081]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Plain photography of ocular fundus
CK2S4 [2001301455]

—

-1.0e+50

—

cases:0.00%

controls:0.36%

—

170

1679

—

Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]

1.1e+00

—

cases:5.20%

controls:1.75%

—

164

1682

—

Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

154

1515

Granulocytes [#/volume] in Blood
30394-1 [3035715]

-1.0e+50

—

cases:0.00%

controls:0.41%

—

173

1705

—

Periodontal treatment
SDA03 [2001310328]

3.4e-01

4.5e-01

—

-1.0e+50

—

6.9e-01

cases:6.36%

controls:4.61%

cases:2.89%

controls:1.87%

—

cases:0.00%

controls:0.29%

—

cases:11.69%

controls:6.24%

162

1633

168

1680

—

173

1707

—

136

1427

Plastic repair of ligament of knee not using prosthetic material, anterior cruciate, arthroscopic
NGE35 [2001308121]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

glucosamine; oral
M01AX05 [21604002]

2.4e-01

—

-1.0e+50

—

cases:2.89%

controls:2.28%

—

cases:0.00%

controls:0.41%

—

168

1673

—

173

1705

—

cetirizine; oral
R06AE07 [21603497]

5.4e-01

4.8e-01

-1.0e+50

—

5.6e-01

6.7e-01

cases:13.29%

controls:8.24%

cases:5.20%

controls:3.27%

cases:0.00%

controls:0.64%

—

cases:5.29%

controls:3.09%

cases:12.34%

controls:6.70%

141

150

1571

164

1656

173

1701

—

161

1633

102

135

1420

Casts [#/volume] in Urine by Automated count
51483-6 [3030467]

1.4e-01

1.0e+00

—

9.3e-01

6.9e-01

cases:3.47%

controls:3.04%

cases:4.05%

controls:1.46%

—

cases:3.53%

controls:1.42%

cases:8.44%

controls:4.40%

167

1660

166

1687

—

164

1661

141

1455

Stomach Pathology biopsy report
66114-0 [40768797]

1.0e+00

—

1.2e+00

cases:4.05%

controls:1.46%

—

cases:5.19%

controls:1.64%

166

1687

—

146

1497

naproxcinod
M01AE18 [40254094]

2.3e-01

2.9e-01

—

3.6e-01

-4.6e-01

cases:10.40%

controls:8.41%

cases:3.47%

controls:2.63%

—

cases:3.53%

controls:2.49%

cases:5.19%

controls:8.02%

144

155

1568

167

1667

—

164

1643

122

146

1400

desonide
D07AB08 [21602112]

—

8.3e-01

—

cases:3.25%

controls:1.45%

—

149

1500

prednisolone
S03BA02 [21605202]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.41%

—

cases:0.00%

controls:0.30%

—

173

1705

—

170

1680

—

propranolol; oral, parenteral
C07AA05 [21601670]

3.4e-01

—

4.4e-01

cases:4.62%

controls:3.33%

—

cases:5.19%

controls:3.42%

165

1655

—

146

1470

Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Spondylolisthesis
M43.1 [45606219]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

acetylcysteine
V03AB23 [21605248]

-1.0e+50

—

cases:0.00%

controls:0.47%

—

173

1704

—

Genetic counselling
Z31.5 [45590715]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Polyarthrosis
M15 [45596490]

—

-1.0e+50

—

cases:0.00%

controls:0.46%

—

154

1515

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.05%

—

cases:0.00%

controls:0.35%

—

173

1694

—

173

1706

—

Limited function/disability NOS
A28 [2002000162]

—

-1.0e+50

—

cases:0.00%

controls:0.71%

—

170

1673

—

Routine child health examination
Z00.1 [45561606]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

CPAP therapy
WX723 [2001310826]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Acute spinal anesthesia for delivery
WX321 [2001310800]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

metoprolol and felodipine
C07FB02 [21601742]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.35%

—

cases:0.00%

controls:0.30%

—

173

1706

—

170

1680

—

Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.41%

—

cases:0.00%

controls:0.53%

173

1705

—

154

1514

glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]

4.7e-01

—

cases:4.05%

controls:2.57%

—

166

1668

—

Health check-up of pregnant person
SPAT1379 [2001700479]

—

-1.0e+50

—

cases:0.00%

controls:0.47%

—

170

1677

—

Sick sinus syndrome
I49.5 [45562354]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.47%

—

cases:0.00%

controls:0.30%

cases:0.00%

controls:0.39%

173

1704

—

170

1680

154

1516

Other medical or dental certificate
WZA90 [2001310883]

—

7.6e-01

—

cases:5.84%

controls:2.83%

—

145

1479

miconazole
D01AC02 [21601921]

—

-1.0e+50

—

cases:0.00%

controls:0.30%

—

170

1680

—

intermediate-acting sulfonamides - combinations
J01EC20 [21602948]

8.9e-01

—

cases:4.05%

controls:1.69%

—

166

1683

—

Rehabilitation Hospital
283X00000X [38004285]

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

Knee symptom/complaint
L15 [2002000639]

—

2.7e-01

—

cases:3.25%

controls:2.50%

—

149

1484

Excessive ear wax
H81 [2002000536]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.58%

—

cases:0.00%

controls:2.10%

173

1685

—

154

1490

antibiotics in combination with other drugs
S01AA20 [21603571]

3.7e-01

—

3.7e-01

cases:7.51%

controls:5.32%

—

cases:7.79%

controls:5.52%

160

1621

—

142

1438

follitropin beta; parenteral
G03GA06 [21602604]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Apolipoprotein A-I [Mass/volume] in Serum or Plasma
1869-7 [3008364]

—

-1.0e+50

—

cases:0.00%

controls:0.85%

—

154

1509

Fracture of upper end of tibia
S82.1 [45579358]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Achilles tendinitis
M76.6 [45596682]

—

-1.0e+50

—

cases:0.00%

controls:0.53%

—

170

1676

—

Contusion of knee
S80.0 [45569633]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

154

1513

norfloxacin; oral
J01MA06 [21603013]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

cases:0.00%

controls:0.92%

—

173

1707

—

154

1508

Cyst in Rathke's pocket
D35.31 [2000501344]

—

1.0e+50

—

cases:3.25%

controls:0.00%

—

149

1522

Other and unspecified ovarian cysts
N83.2 [45539066]

—

-1.0e+50

—

cases:0.00%

controls:0.30%

—

170

1680

—

tranexamic acid; oral, parenteral
B02AA02 [21601036]

7.4e-01

—

-1.0e+50

—

cases:2.89%

controls:1.40%

—

cases:0.00%

controls:0.42%

—

168

1688

—

170

1678

—

Ocular fundus photography for diabetic retinopathy screening
CL2S4 [2001301465]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Bicipital tendinitis
M75.2 [45557984]

-1.0e+50

—

cases:0.00%

controls:0.41%

—

173

1705

—

Macroprolactin [Units/volume] in Serum or Plasma
74953-1 [44816844]

2.3e+00

—

cases:2.89%

controls:0.29%

—

168

1707

—

Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

154

1512

cyanocobalamin; nasal, oral, parenteral
B03BA01 [21601121]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.29%

—

cases:0.00%

controls:0.39%

173

1707

—

154

1516

Excessive and frequent menstruation with regular cycle
N92.0 [45577544]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Supervision of normal first pregnancy
Z34.0 [45595500]

—

-1.0e+50

—

cases:0.00%

controls:0.66%

—

154

1512

Atrial premature depolarization
I49.1 [45552795]

—

-1.0e+50

—

cases:0.00%

controls:0.59%

—

154

1513

pioglitazone; oral
A10BG03 [21600782]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

General and Unspecified, Result test/procedure
A60 [2002000194]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.70%

—

cases:0.00%

controls:0.53%

173

1700

—

154

1514

ticagrelor; oral
B01AC24 [40252640]

—

-1.0e+50

—

cases:0.00%

controls:0.39%

—

154

1516

Fever
A03 [2002000144]

—

-1.0e+50

8.3e-01

—

cases:0.00%

controls:0.42%

cases:3.25%

controls:1.45%

—

170

1678

149

1500

combinations of corticosteroids
D07XB30 [21602188]

5.7e-01

2.4e-02

—

-1.8e-01

6.9e-01

cases:16.18%

controls:9.87%

cases:3.47%

controls:3.39%

—

cases:2.94%

controls:3.50%

cases:18.18%

controls:9.99%

169

145

1543

167

1654

—

165

1626

152

126

1370

Excision of lesion of eyelid
CBB30 [2001300933]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

Malignant tumour
130 [2001600128]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.53%

—

cases:0.00%

controls:0.66%

173

1703

—

154

1512

Presence of intraocular lens
Z96.1 [45585885]

—

-1.0e+50

—

cases:0.00%

controls:0.71%

—

170

1673

—

calcipotriol; ointment
D05AX02 [21602039]

-1.0e+50

—

cases:0.00%

controls:0.35%

—

173

1706

—

almotriptan; oral
N02CC05 [21604380]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.41%

—

cases:0.00%

controls:0.39%

173

1705

—

154

1516

orphenadrine, combinations
M03BC51 [21604113]

1.2e+00

—

7.1e-01

cases:6.94%

controls:2.22%

—

cases:5.84%

controls:2.96%

161

1674

—

145

1477

rivaroxaban; oral
B01AF01 [43534761]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.64%

—

cases:0.00%

controls:0.35%

—

173

1701

—

173

1706

—

Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]

—

1.0e+00

—

cases:3.25%

controls:1.18%

—

149

1504

Vasomotor and allergic rhinitis
J30 [45605885]

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]

6.8e-01

—

1.4e+00

7.6e-01

cases:6.36%

controls:3.33%

—

cases:4.12%

controls:1.01%

cases:7.14%

controls:3.48%

162

1655

—

163

1668

143

1469

Noninvasive ventilation
WX725 [2001310828]

—

-1.0e+50

—

cases:0.00%

controls:0.39%

—

154

1516

Infection following a procedure, not elsewhere classified
T81.4 [45575538]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.70%

—

cases:0.00%

controls:0.30%

—

173

1700

—

170

1680

—

Pain in the jaw joint UNS
K07.63 [2000502794]

—

-1.0e+50

—

cases:0.00%

controls:0.33%

—

154

1517

Kuhnt-Junius degeneration
H35.30 [2000502314]

—

-1.0e+50

—

cases:0.00%

controls:0.29%

—

173

1707

—

bromocriptine; oral
N04BC01 [21604473]

—

1.0e+50

—

cases:3.53%

controls:0.00%

cases:3.25%

controls:0.00%

—

164

1685

149

1522

Public health laboratory ask at order entry panel
81959-9 [21494755]

1.1e+00

—

cases:3.47%

controls:1.17%

—

167

1692

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3021387) Prolactin [Units/volume] in Serum or Plasma

22.55

102.41

4.4

1.2

330.32

285.63

mu/l

0.51

(3009214) Lutropin [Units/volume] in Serum or Plasma

10.30

37.01

2.3

1.2

4.90

7.82

u/l

1.15

(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma

109

6.70

30.29

2.9

3.3

4.15

4.57

pmol/l

1.77

(3023323) Follitropin [Units/volume] in Serum or Plasma

5.60

20.42

2.1

1.2

23.42

26.92

iu/l

0.26

(3002030) Lymphocytes/Leukocytes in Blood

149

955

2.72

11.04

7.1

6.3

29.80

27.96

1.18

144

906

(3024980) IgG subclass 4 [Mass/volume] in Serum

5.84

10.61

3.3

1.3

0.79

0.48

g/l

0.71

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

141

3.34

9.87

5.7

3.2

1.21

1.23

mmol/l

0.75

124

(3006504) Eosinophils/Leukocytes in Blood

144

937

2.54

9.87

7.2

6.2

2.60

2.83

0.68

137

876

(3026725) Estradiol (E2) [Moles/volume] in Serum or Plasma

9.05

9.80

2.5

1.2

0.31

0.18

nmol/l

0.71

(3019069) Monocytes/Leukocytes in Blood

144

939

2.53

9.79

7.2

6.3

9.04

8.68

0.46

139

879

(3018418) pH of Serum or Plasma

105

599

2.43

9.52

5.2

3.6

7.40

0.02

420

(3022096) Basophils/Leukocytes in Blood

142

939

2.43

9.08

7.3

6.3

0.70

0.68

0.13

137

873

(3019198) Lymphocytes [#/volume] in Blood

153

1048

2.49

9.01

6.7

6.3

1.94

1.96

e9/l

0.04

134

922

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

142

945

2.41

8.86

13.9

7.0

1.21

mmol/l

0.45

117

811

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

133

866

2.35

8.64

13.0

6.2

1.21

mmol/l

0.13

127

804

(3026782) Osmolality of Urine

367

2.48

8.59

4.4

2.8

477.05

516.25

mosm/kgh2o

0.89

321

(42870588) Differential panel, method unspecified - Blood

109

654

2.32

8.57

6.2

5.8

—

(3006315) Basophils [#/volume] in Blood

149

1032

2.36

8.20

6.7

6.2

0.04

e9/l

0.06

127

881

(3017181) Myelocytes/Leukocytes in Blood

170

2.90

8.11

4.4

5.0

1.11

1.02

0.07

(3002179) Metamyelocytes/Leukocytes in Blood

158

2.96

8.09

4.4

4.9

0.50

0.63

0.17

(3024561) Albumin [Mass/volume] in Serum or Plasma

131

863

2.27

8.07

7.7

4.7

35.37

36.08

g/l

0.75

124

813

(3021440) Promyelocytes/Leukocytes in Blood

159

2.94

8.00

4.5

5.1

0.13

0.18

(3001604) Monocytes [#/volume] in Blood

148

1030

2.32

7.93

6.7

6.2

0.59

0.56

e9/l

0.72

127

881

(3013115) Eosinophils [#/volume] in Blood

150

1063

2.28

7.51

6.8

6.4

0.18

0.19

e9/l

0.41

128

932

(40761536) Microorganisms panel - Urine sediment

147

2.91

7.43

5.0

4.0

—

(3044290) Cell count panel - Cerebral spinal fluid

4.58

7.36

1.4

1.3

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

303

2.40

7.22

3.1

2.2

2.21

2.32

g/l

0.81

281

(3025159) Blasts/Leukocytes in Blood

169

2.75

7.12

4.6

5.4

0.00

0.16

0.80

(4027681) Cerebrospinal fluid IgG ratio and IgG index

9.78

6.88

1.4

1.2

0.46

0.47

ratio

—

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

11.45

6.88

1.3

1.1

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

155

1134

2.23

6.88

10.3

9.9

3.94

4.03

e9/l

0.21

136

988

(3009991) Angiotensin converting enzyme [Enzymatic activity/volume] in Cerebral spinal fluid

10.49

6.62

1.3

1.1

1.16

1.02

u/l

—

(3021589) Normoblasts [#/volume] in Blood

128

882

2.07

6.49

19.4

11.3

0.00

e9/l

0.25

104

708

(3032080) INR in Blood by Coagulation assay

126

865

2.06

6.43

10.0

12.6

1.13

1.23

inr

1.80

106

722

(3012320) Pathologist interpretation of Cerebral spinal fluid tests

+∞

6.28

1.2

0.0

—

(3016543) Leukocytes [#/volume] in Cerebral spinal fluid

3.83

6.19

1.3

58.33

5.67

e6/l

0.43

(3027475) Erythrocytes [#/volume] in Cerebral spinal fluid

3.83

6.19

1.5

1.4

8.69

20.64

e6/l

0.63

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

3.55

5.58

1.7

2.2

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

6.50

5.47

2.7

2.5

33.08

31.81

0.31

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

320

2.10

5.18

1.8

—

(40764127) Haemophilus influenzae DNA [Presence] in Specimen by NAA with probe detection

10.36

5.07

1.3

—

(3037875) Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection

10.36

5.07

1.3

1.4

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

3.18

4.97

1.2

1.1

—

(40760892) CBC W Ordered Manual Differential panel - Blood

479

1.93

4.89

6.4

5.1

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

180

1480

2.17

4.84

9.3

4.3

15.08

14.78

pmol/l

0.76

175

1362

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

6.75

4.83

1.5

1.2

—

nmol/l

—

(3032699) Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection

9.32

4.83

1.3

1.5

—

(1001509) Gas and Carbon monoxide and Electrolytes panel - Arterial blood

7.42

4.70

2.7

2.1

—

(4035726) Immunohistochemistry procedure

163

2.36

4.68

1.5

1.3

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

6.37

4.66

1.0

1.1

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

241

2.15

4.66

1.8

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

198

2.25

4.65

4.0

3.1

—

(3021901) Oxygen saturation in Capillary blood

4.75

4.64

6.0

1.8

89.86

88.61

0.23

(40767503) Oxygen content in Capillary blood by calculation

4.27

4.50

3.5

1.9

15.61

16.04

0.19

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

231

2.13

4.42

1.8

—

(3023368) Bacteria identified in Blood by Culture

519

1.85

4.38

7.8

4.5

—

(3030467) Casts [#/volume] in Urine by Automated count

545

1.84

4.38

4.5

3.1

0.32

0.43

e6/l

0.39

393

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

6.49

4.34

1.0

1.1

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

5.01

4.25

1.3

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

4.82

4.12

6.2

1.6

5.69

6.07

pmol/l

0.13

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

4.82

4.12

1.3

1.7

—

(3016018) Differential panel - Cerebral spinal fluid

5.76

4.02

1.4

1.0

—

(40768797) Stomach Pathology biopsy report

271

1.99

3.96

1.3

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

3.33

3.85

1.3

1.4

—

(1616796) Gas panel - Central venous blood

3.76

3.77

11.7

1.8

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

4.31

3.76

1.3

—

(3013707) Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method

174

1462

1.89

3.71

5.3

4.4

12.32

11.52

mm/h

0.38

169

1364

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

131

2.30

3.71

2.3

2.4

—

7.28

—

(3011391) Calcitriol [Moles/volume] in Serum or Plasma

5.81

3.70

1.2

1.3

108.56

105.50

pmol/l

—

(3028626) Oxygen [Partial pressure] in Capillary blood

3.67

3.68

11.7

1.9

8.26

7.99

kpa

0.20

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

4.17

3.65

1.3

1.6

—

(3019977) pH of Arterial blood

210

2.04

3.65

20.9

10.2

7.42

0.00

125

(3002582) Erythrocytes [#/volume] in Urine

642

1.71

3.61

4.4

3.2

24.50

132.18

e6/l

0.53

484

(3000012) Reticulocyte production index

4.93

3.60

3.4

2.5

0.85

0.87

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

5.47

3.55

1.3

1.1

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

3.11

3.48

2.7

1.6

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

380

1.79

3.45

1.9

1.7

492.60

36562950.58

pmol/l

0.50

320

(3000850) Epithelial cells [#/volume] in Urine

426

1.74

3.32

3.9

2.5

5.00

5.10

e6/l

0.03

391

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

3.15

3.31

1.3

1.4

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

3.48

3.28

1.5

—

(3030136) 5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma

8.77

3.28

2.7

4.6

79.50

60.14

nmol/l

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

488

1.71

3.25

1.4

1.3

0.96

1.24

u/ml

0.36

131

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

4.31

3.23

1.2

1.3

—

(3023410) Appearance of Cerebral spinal fluid

4.31

3.23

1.5

—

(3018095) Leukocytes [#/volume] in Urine

733

1.64

3.17

4.9

4.0

18.97

94.48

e6/l

1.24

507

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

134

2.16

3.12

2.0

1.6

—

(3048689) Calprotectin [Mass/mass] in Stool

261

1.86

3.11

2.2

2.4

107.98

109.30

ug/g

0.02

208

(3042111) Morphology [Interpretation] in Bone marrow Narrative

3.98

3.02

1.9

1.4

—

(3022145) Colonoscopy Study observation

225

1.89

3.00

1.2

1.4

—

(3012565) Volume of 24 hour Urine

10.19

2.99

1.4

3.2

2390.00

2459.00

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

577

1.64

2.99

3.0

3.1

4573.92

1334.06

ng/l

0.64

485

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

111

856

1.60

2.95

2.1

100.64

98.50

pmol/l

0.20

427

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

4.84

2.94

1.3

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

4.84

2.94

1.5

1.1

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

3.56

2.94

1.4

—

(4062490) Immunoglobulin typing, IgG

4.22

2.91

4.0

1.4

—

(3023520) Reticulocytes [#/volume] in Blood

168

1.98

2.85

3.5

2.6

73.92

70.72

e9/l

0.15

118

(3033386) Bacteria [Presence] in Cerebral spinal fluid by Light microscopy

8.49

2.76

1.4

1.0

—

(4024509) Urine culture

2.32

2.72

2.6

1.9

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

4.33

2.70

1.4

1.0

—

(3022806) Fractional oxyhemoglobin in Capillary blood

3.86

2.70

2.7

1.5

86.59

89.57

—

(3004809) Band form neutrophils/Leukocytes in Blood

3.86

2.70

5.0

3.6

0.67

1.29

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

448

1.64

2.70

1.5

1.8

0.83

1.21

mg/l

1.27

351

(3007853) Bacteria identified in Skin by Aerobe culture

219

1.83

2.63

2.4

1.7

—

(3008733) Herpes simplex virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

7.27

2.56

1.0

—

(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma

3.33

2.55

1.5

1.1

—

(3037522) Nuclear Ab [Titer] in Serum

294

1.71

2.52

1.4

260.00

478.87

titre

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

455

1.61

2.52

2.4

2.2

—

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

194

1750

1.89

2.51

8.5

5.4

1.43

1.94

mu/l

7.30

185

1622

(3014148) Varicella zoster virus Ab [Titer] in Serum

4.48

2.49

1.3

1.1

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

2.44

1.4

1.1

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

2.44

2.0

1.7

19.13

6.09

u/ml

—

(40763082) Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction

5.11

2.42

1.2

1.3

268.50

252.67

u/l

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

331

1.66

2.41

3.3

3.0

0.81

e6/l

0.01

169

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

2.70

2.40

1.2

1.3

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

3.12

2.39

1.5

1.2

—

(3042631) Mycobacterium sp identified in Specimen

3.73

2.38

2.1

3.0

—

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

6.36

2.38

4.0

2.5

—

(3002079) Sodium [Moles/time] in 24 hour Urine

6.36

2.38

1.2

1.1

149.60

144.08

mmol/24h

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

2.91

2.38

1.2

1.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

587

1.54

2.35

5.3

3.2

0.00

0.01

estimate

0.50

175

(3042936) Bacteria identified in Isolate by Culture

276

1.69

2.32

3.0

2.2

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

112

899

1.50

2.30

3.3

2.7

—

estimate

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

2.50

2.24

3.7

1.8

24.99

24.60

mmol/l

0.18

(3015377) Calcium [Moles/volume] in Serum or Plasma

684

1.50

2.24

4.5

3.4

2.32

2.35

mmol/l

1.64

619

(3035715) Granulocytes [#/volume] in Blood

2.94

2.24

8.0

3.0

4.10

4.83

e9/l

—

(3026008) Bacteria identified in Urine by Culture

556

1.53

2.24

5.5

3.2

—

(3009508) Creatinine [Moles/volume] in Urine

675

1.50

2.23

3.3

3.2

7.63

7.64

mmol/l

0.00

574

(3012516) Albumin [Mass/volume] in Urine

620

1.51

2.23

3.0

3.3

14.76

51.41

mg/l

3.99

383

(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

5.65

2.22

1.0

1.1

—

(3016502) Oxygen saturation in Arterial blood

191

1.79

2.22

23.4

10.5

94.76

96.05

0.62

186

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

102

810

1.48

2.17

5.9

3.6

0.03

0.00

estimate

0.49

178

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

3.77

2.17

1.1

1.2

—

(3020682) Albumin/Creatinine [Ratio] in Urine

636

1.49

2.09

4.1

4.0

1.56

8.94

mg/mmol

5.00

387

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

701

1.48

2.09

4.0

3.4

37.41

30.44

u/l

0.67

671

(3032700) Glomerular basement membrane Ab [Units/volume] in Serum

4.08

2.05

1.2

1.1

—

(3045142) Bone marrow Pathology biopsy report

4.08

2.05

1.0

1.1

—

(3026493) Urate [Moles/volume] in Serum or Plasma

497

1.50

1.96

2.1

2.6

351.96

339.76

umol/l

0.41

430

(3035933) Granulocytes/Leukocytes in Blood

2.52

1.96

9.6

3.1

48.45

60.16

0.89

(3038177) Helicobacter pylori Ab [Presence] in Serum

3.03

1.95

1.1

—

(3007164) IgA [Mass/volume] in Serum or Plasma

439

1.50

1.87

1.5

1.3

2.56

2.48

g/l

0.14

247

(40760888) Immunoglobulin light chains.free panel - Serum

3.11

1.81

2.9

6.3

—

(3019309) Folate [Moles/volume] in Red Blood Cells

303

1.56

1.80

1.8

1.6

1324.69

1155.48

nmol/l

0.53

221

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

195

1801

1.70

1.79

7.5

6.2

39.54

39.30

mmol/mol

0.14

189

1704

(40768804) Tissue Pathology biopsy report

775

1.42

1.79

2.2

2.0

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

313

1.55

1.76

3.5

3.2

3.09

2.56

e6/l

0.15

151

(3021879) Hepatitis B virus core Ab [Presence] in Serum

150

1.75

1.72

1.4

1.5

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

336

1.51

1.63

2.2

1.9

—

(3025941) Bacteria identified in Stool by Culture

107

1.85

1.60

1.3

1.2

—

(3044640) Blood type and Crossmatch panel - Blood

626

1.41

1.60

2.6

2.2

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

115

1.81

1.59

1.2

1.1

—

(3021788) Differential panel - Synovial fluid

2.48

1.55

1.4

1.2

—

(3052851) Hemolysis interference index of Serum or Plasma

2.22

1.53

4.8

3.0

1.83

2.87

index

—

(3009595) Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection

3.38

1.53

1.4

1.3

—

(3013201) Beta-2-Microglobulin [Mass/volume] in Serum or Plasma

3.38

1.53

1.2

1.3

2.52

3.38

mg/l

—

(4268621) Lupus anticoagulant assay

2.64

1.52

1.7

2.0

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

2.49

1.49

1.4

1.5

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

2.49

1.49

1.4

1.5

—

(3021601) Nitrite [Presence] in Urine by Test strip

122

1048

1.37

1.49

5.8

3.8

0.00

estimate

-0.00

212

(3013139) Helicobacter pylori Ag [Presence] in Stool

126

1.74

1.46

1.2

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

142

1.69

1.45

1.2

141.03

149.93

u/ml

—

(3020630) Protein [Mass/volume] in Serum or Plasma

158

1.66

1.45

2.0

2.2

63.52

67.39

g/l

1.14

147

(3014576) Chloride [Moles/volume] in Serum or Plasma

267

1.51

1.43

9.4

6.5

104.89

104.12

mmol/l

0.34

267

(3035350) Ketones [Presence] in Urine by Test strip

123

1063

1.35

1.42

5.8

3.8

0.00

7.45

estimate

0.50

218

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

2.24

1.38

1.1

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

2.24

1.38

1.1

1.2

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

2.65

1.37

1.0

1.1

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

2.02

1.35

1.2

—

(21494755) Public health laboratory ask at order entry panel

213

0.54

1.28

1.5

1.4

—

(3009261) Glucose [Presence] in Urine by Test strip

122

1064

1.33

1.27

5.7

3.9

0.00

estimate

-0.00

196

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

1.96

1.25

1.6

1.7

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

1.78

1.25

2.5

2.2

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

232

1.50

1.24

1.5

1.6

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

109

1.71

1.23

2.0

1.6

—

(3005322) IgE [Units/volume] in Serum or Plasma

125

1.66

1.22

1.2

1.3

87.98

241.99

u/ml

1.21

114

(40768443) Skin Pathology biopsy report

1.80

1.22

1.1

1.2

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

2.67

1.22

3.2

3.5

4.80

3.35

nmol/l

—

(3012544) pH of Venous blood

210

1.50

1.16

6.6

3.6

7.38

7.39

0.40

119

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

386

1.38

1.16

3.9

3.7

47.68

280.87

ng/l

1.70

296

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

751

1.31

1.14

5.6

3.5

25.68

37.54

ng/l

0.96

519

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

290

1.42

1.12

1.8

1.6

—

(3030366) Cystatin C [Mass/volume] in Serum or Plasma

1.87

1.11

10.4

2.4

1.41

1.42

mg/l

0.01

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

2.41

1.09

1.0

1.2

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

2.16

1.06

1.6

1.2

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

2.30

1.04

1.0

1.1

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

251

1.42

1.02

2.5

2.7

5.60

6.71

umol/l

0.38

227

(3000991) Gas panel - Venous blood

165

1.51

1.02

14.3

8.0

—

(3029937) Albumin [Presence] in Urine by Test strip

590

1.30

1.01

5.4

3.8

0.00

estimate

-0.00

198

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

101

1.63

0.96

1.4

1.3

—

(3028026) IgM [Mass/volume] in Serum or Plasma

134

1.54

0.95

1.7

1.5

1.11

1.39

g/l

0.49

125

(3019832) Treponema pallidum Ab [Presence] in Serum

168

1.48

0.94

1.5

1.9

—

(3023419) Bacteria identified in Sputum by Culture

2.10

0.90

2.7

2.3

—

(40764999) Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M

192

1827

1.39

0.87

25.8

14.9

80.38

82.63

ml/min/173m2

0.71

179

1697

(40758558) Short blood count panel - Blood

602

1.26

0.85

8.0

6.7

—

(3015736) pH of Urine

855

1.24

0.82

4.4

3.3

6.15

6.16

0.03

494

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

1.70

0.80

1.7

1.8

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

1.69

0.79

1.1

2.0

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

1.73

0.77

1.2

1.6

—

(3022313) Gas panel - Capillary blood

1.65

0.73

9.5

3.3

—

(3037756) Immunofixation for Serum or Plasma

1.77

0.72

1.4

1.6

—

(3000494) Fungus identified in Specimen by Culture

261

1.31

0.67

2.2

1.5

—

(3046279) Procalcitonin [Mass/volume] in Serum or Plasma

1.60

0.66

4.1

1.6

1.02

5.02

ug/l

0.48

(3007628) Bicarbonate [Moles/volume] standard in Venous blood

121

1.44

0.64

4.9

3.3

24.88

24.65

mmol/l

0.10

121

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

198

1911

1.35

0.64

26.7

15.5

24.89

22.49

mg/l

0.39

178

1562

(46236952) Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M

156

1.38

0.64

2.5

2.7

65.80

66.95

ml/min/173m2

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

377

1.24

0.60

1.4

1.7

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

203

1.32

0.59

2.0

2.6

23.00

30.36

u/l

1.50

170

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

194

0.70

0.57

18.4

7.4

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

187

1798

1.26

0.57

4.9

4.2

1.43

1.28

mmol/l

1.94

178

1662

(3003327) Ova and parasites identified in Stool by Light microscopy

1.45

0.53

1.8

1.3

—

(3004588) Protein electrophoresis panel - Serum or Plasma

135

1.36

0.53

1.4

2.0

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

189

1.30

0.52

1.9

1.6

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

1.40

0.51

1.3

1.2

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

208

1.28

0.51

6.2

3.4

5.90

5.74

kpa

0.27

203

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

190

1836

1.25

0.50

5.8

5.0

5.82

5.93

mmol/l

0.56

182

1706

(3019060) Gas panel - Arterial blood

110

1.39

0.50

33.3

8.4

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

1.51

0.48

1.1

1.2

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

133

1251

1.16

0.47

3.3

3.2

—

(1761482) Bacteria [#/volume] in Urine by Culture

1.41

0.45

7.6

4.8

—

(3002256) Pathology report gross observation

230

1.25

0.45

1.4

1.3

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

505

1.17

0.44

6.6

4.6

1.88

2.39

ug/l

0.31

449

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

1.63

0.43

1.0

—

(3011288) Drugs identified in Urine by Screen method Nominal

1.44

0.43

2.5

1.5

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.41

0.0

1.3

—

(3025149) Bordetella pertussis IgA Ab [Units/volume] in Serum

0.00

0.41

0.0

1.1

—

4.38

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

0.00

0.41

0.0

1.2

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

0.00

0.41

0.0

16.5

—

795.00

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

0.41

0.0

1.0

—

(3044941) Cell count panel - Synovial fluid

1.48

0.40

1.2

—

(1761868) Lipid panel - Serum or Plasma

791

1.14

0.40

4.1

3.1

—

(3000330) Specific gravity of Urine by Test strip

106

1.34

0.40

5.1

3.5

1.02

ratio

0.25

101

(4146454) Self-monitoring of blood glucose

0.00

0.40

0.0

2.8

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

366

1.18

0.39

1.4

1.3

1.63

7.87

u/ml

2.60

154

(3000764) Benzodiazepines [Presence] in Urine

1.39

0.39

2.0

1.3

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

144

1372

1.14

0.39

4.4

3.2

62.76

46.41

u/l

0.57

136

1304

(3015916) Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma

1.40

0.38

2.8

1.7

4.08

111.74

u/ml

—

(36660697) Celiac disease serology panel - Serum

189

1.24

0.38

1.2

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

1.32

0.37

2.2

1.2

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

1.36

0.37

1.0

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.65

0.36

1.2

1.1

0.89

g/l

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

388

1.17

0.36

1.5

1.3

17.76

29.03

iu/ml

1.05

122

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

1.33

0.36

1.4

2.2

—

(3023465) Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.64

0.36

1.2

1.8

6.78

9.89

g/l

—

(3028707) Methadone [Presence] in Urine by Screen method

1.41

0.35

1.0

1.3

—

(3003740) Influenza virus B Ag [Presence] in Specimen

1.34

0.34

1.0

1.1

—

(3002523) Influenza virus A Ag [Presence] in Specimen

1.34

0.34

1.0

1.1

—

(3047181) Lactate [Moles/volume] in Blood

1.36

0.31

67.3

14.6

1.06

1.22

mmol/l

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

120

1.27

0.31

33.9

10.6

24.08

24.46

mmol/l

0.22

115

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

217

0.81

0.31

1.9

2.2

3.52

3.47

ratio

0.08

173

(3027008) Opiates [Presence] in Urine

1.33

0.30

2.0

1.3

—

(3027944) Amphetamines [Presence] in Urine

1.33

0.30

2.0

1.3

—

(3024928) Oxygen saturation in Venous blood

1.28

0.30

9.6

2.9

69.94

57.31

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

1.24

0.27

1.3

1.1

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

1.24

0.27

1.3

1.1

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

311

1.15

0.27

1.3

1.5

—

(42529406) Shigella sp [Presence] in Stool by Culture

1.22

0.27

1.3

1.1

—

(3001019) Free T4 and TSH panel - Serum or Plasma

1.28

0.27

1.7

1.8

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.66

0.26

1.0

1.1

1.57

g/l

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

195

1914

1.16

0.25

6.4

5.8

2.65

2.73

mmol/l

0.62

188

1790

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

199

1.17

0.24

5.1

4.4

203.82

8.30

ug/l

0.46

163

(3050129) First trimester maternal screen panel - Serum or Plasma

1.29

0.23

2.2

1.5

—

(3019150) Specific gravity of Urine by Refractometry

480

1.11

0.23

5.3

3.6

1.02

kg/l

0.56

312

(3000492) Spirometry study

210

1.16

0.23

1.5

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

0.21

0.0

1.1

—

(3007461) Platelets [#/volume] in Blood

208

2055

1.21

0.21

39.3

23.4

257.74

252.54

e9/l

0.38

201

2026

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.21

0.0

1.6

—

(3003694) ABO and Rh group [Type] in Blood

532

1.10

0.20

1.5

1.4

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.20

0.0

6.4

—

8.70

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

0.20

0.0

1.0

—

(3010813) Leukocytes [#/volume] in Blood

208

2056

1.20

0.19

39.2

23.4

6.85

6.64

e9/l

0.75

201

2016

(3026361) Erythrocytes [#/volume] in Blood

208

2056

1.20

0.19

39.1

23.3

4.46

4.51

e12/l

0.72

201

2015

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

849

1.08

0.19

2.2

2.0

1.54

1.37

mmol/l

1.02

736

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

118

1.20

0.19

1.4

2.2

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

192

1889

1.13

0.19

5.8

5.1

4.60

4.67

mmol/l

0.50

184

1770

(3048929) Epstein Barr virus Ab [Presence] in Serum

1.21

0.18

1.9

1.3

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

389

1.10

0.17

5.1

4.1

21.59

20.47

0.19

168

(4034850) Laboratory test

0.74

0.17

3.2

12.7

—

(3049717) Cytology report of Urine Cyto stain

0.71

0.17

2.0

2.4

—

(3016879) Cocaine [Presence] in Urine

1.12

0.15

2.2

1.3

—

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

160

0.87

0.14

1.6

1.4

—

(3028300) Cannabinoids [Presence] in Urine

1.20

0.14

2.1

1.3

—

(3045414) Leukocytes [Presence] in Urine

190

1.12

0.13

1.9

2.1

0.00

estimate

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

189

0.89

0.12

2.2

2.1

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

190

1878

1.08

0.12

5.7

5.0

1.42

1.48

mmol/l

1.28

183

1752

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

207

0.91

0.10

1.8

2.2

—

(3008898) HLA-B27 [Presence]

1.16

0.09

1.0

1.1

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

223

1.09

0.09

1.3

1.5

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

113

0.88

0.08

1.7

1.3

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

1.04

0.08

1.0

1.2

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

0.78

0.08

1.2

2.0

0.00

g/l

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

1.10

0.08

2.0

1.8

—

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

0.82

0.07

1.2

2.2

0.60

0.74

g/l

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.03

0.07

1.1

1.9

3.14

3.06

g/l

—

(3007930) Methemoglobin/Hemoglobin.total in Blood

1.03

0.07

60.6

11.0

0.64

0.85

—

(1002224) Polysomnography panel

120

1.09

0.05

1.0

1.1

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

299

1.04

0.04

3.6

2.8

0.93

0.66

ug/l

0.59

175

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

123

1.06

0.01

3.5

2.4

1.47

1.25

0.42

123

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

101

0.99

0.00

1.0

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

121

0.99

0.00

2.7

2.4

0.72

0.63

0.27

121

(3045424) Erythrocytes [Presence] in Urine

1.03

0.00

1.5

2.1

0.00

estimate

—

(3022621) pH of Urine by Test strip

185

0.97

0.00

2.7

2.6

5.92

6.18

0.91

120

(40761511) CBC panel - Blood by Automated count

195

1948

1.01

0.00

26.7

13.5

—

(3000213) Normetanephrine [Moles/time] in 24 hour Urine

0.00

0.0

1.3

—

1.70

—

(3026048) Bordetella pertussis IgG Ab [Units/volume] in Serum

0.00

0.0

1.2

—

25.85

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

0.00

0.0

1.0

—

(3044007) Cell count panel - Peritoneal fluid

0.00

0.0

1.7

—

(3028009) Chlamydia trachomatis IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

4.27

—

(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.3

—

(40765096) Chromosome analysis panel by Banding

0.00

0.0

1.0

—

(3035457) Cefaclor IgE Ab [Units/volume] in Serum

0.00

0.0

1.0

—

0.02

—

(3036185) Alkaline phosphatase.liver 2 [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

7.86

—

(3006109) Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

-0.00

0.0

1.0

—

102.00

—

(3008116) Ketones [Moles/volume] in Urine by Test strip

0.00

-0.00

0.0

1.2

—

(3043410) Blood group antigens tested for on Red Blood Cells

0.00

-0.00

0.0

1.3

—

(3002619) Bacteria identified in Specimen by Culture

0.00

-0.00

0.0

1.3

—

(42529582) MDA5 Ab [Presence] in Serum by Line blot

0.00

-0.00

0.0

1.0

—

(3006462) Nitrate [Presence] in Urine

0.00

-0.00

0.0

5.3

—

(40765089) Chromosome analysis panel - Blood by G-banded

0.00

-0.00

0.0

1.0

—

(3033799) Differential panel - Peritoneal fluid

0.00

-0.00

0.0

1.4

—

(3028433) Virus identified in Specimen by Culture

0.00

-0.00

0.0

1.0

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.95

-0.00

1.1

1.8

4.15

4.39

g/l

—

(3023081) Carboxyhemoglobin/Hemoglobin.total in Blood

0.92

-0.00

59.9

10.0

1.24

1.57

—

(3038769) Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay

0.00

-0.00

0.0

1.0

—

28.00

—

(3013637) Mi-2 Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3015956) Eosinophils/Leukocytes in Blood by Manual count

0.00

-0.00

0.0

2.8

—

2.20

—

(3035062) Alkaline phosphatase.liver 1 [Enzymatic activity/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

50.44

—

(3004446) Plasmodium sp identified in Blood by Light microscopy

0.00

-0.00

0.0

3.0

—

(3002348) Coagulation factor XII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

-0.00

0.0

1.0

—

(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3021197) Magnesium Ionized [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

0.60

—

(3037692) Legionella sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3013566) Clostridioides difficile [Presence] in Stool by Organism specific culture

0.00

-0.00

0.0

1.3

—

(3052592) Norovirus Ag [Presence] in Stool

0.00

-0.00

0.0

1.4

—

(42528593) TIF1-gamma Ab [Presence] in Serum by Line blot

0.00

-0.00

0.0

1.0

—

(3044936) Clostridioides difficile toxin A+B [Presence] in Stool by Immunoassay

0.00

-0.00

0.0

1.4

—

(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.95

-0.00

1.1

1.8

3.60

3.65

g/l

—

(3028334) Neisseria gonorrhoeae [Presence] in Specimen by Organism specific culture

0.00

-0.00

0.0

1.7

—

(3009306) Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

4.6

—

5.41

—

(42869547) Procollagen type III.N-terminal propeptide [Mass/volume] in Serum

0.00

-0.00

0.0

1.0

—

7.94

—

(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.95

-0.00

1.1

1.8

7.56

g/l

—

(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(42529598) SUMO-activating enzyme subunit 1 Ab [Presence] in Serum by Line blot

0.00

-0.00

0.0

1.0

—

(3001850) Coagulation factor XI activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

-0.00

0.0

1.0

—

(40768793) Breast Pathology biopsy report

0.98

-0.00

1.3

1.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PITUDISNAS and mortality.

Females

Parameter	HR [95% CI]	p-value
E4_PITUDISNAS	2.384 [1.81, 3.14]	< 0.001
Birth year	0.992 [0.98, 1.0]	0.063

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 396 females with E4_PITUDISNAS died.

Males

Parameter	HR [95% CI]	p-value
E4_PITUDISNAS	1.387 [0.99, 1.95]	0.06
Birth year	0.989 [0.98, 1.0]	0.015

During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 288 males with E4_PITUDISNAS died.

Mortality risk

Mortality risk for people of age

years, who have E4_PITUDISNAS.

N-year risk	Females	Males
1	0.202%	0.217%
5	1.248%	1.664%
10	3.13%	4.363%
15	5.77%	8.112%
20	10.357%	13.946%

Relationships between endpoints

↥

Index endpoint: E4_PITUDISNAS – Disorders of pituitary gland, other and/or unspecified

GWS hits: 3

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Disorders of pituitary gland, other and/or unspecified

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints